



**HAL**  
open science

## Extraocular muscle stem cells exhibit distinct cellular properties associated with non-muscle molecular signatures

Daniela Di Girolamo, Maria Benavente-Diaz, Melania Murolo, Alexandre Grimaldi, Priscilla Thomas Lopes, Brendan Evano, Mao Kuriki, Stamatia Gioftsidi, Vincent Laville, Jean-Yves Tinevez, et al.

► **To cite this version:**

Daniela Di Girolamo, Maria Benavente-Diaz, Melania Murolo, Alexandre Grimaldi, Priscilla Thomas Lopes, et al.. Extraocular muscle stem cells exhibit distinct cellular properties associated with non-muscle molecular signatures. *Development* (Cambridge, England), 2024, 151 (4), pp.dev202144. 10.1242/dev.202144 . pasteur-04779435v2

**HAL Id: pasteur-04779435**

**<https://pasteur.hal.science/pasteur-04779435v2>**

Submitted on 14 Nov 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## Extraocular muscle stem cells exhibit distinct cellular properties associated with non-muscle molecular signatures

Daniela Di Girolamo<sup>1,2#</sup>, Maria Benavente-Diaz<sup>1,2,3#</sup>, Melania Murolo<sup>1,2‡</sup>, Alexandre Grimaldi<sup>1,2,3‡</sup>, Priscilla Thomas Lopes<sup>1,2</sup>, Brendan Evano<sup>1,2</sup>, Mao Kiruki<sup>1,2</sup>, Stamatia Gioftsidis<sup>4,5,6</sup>, Vincent Laville<sup>1,2</sup>, Jean-Yves Tinevez<sup>7</sup>, Gaëlle Letort<sup>8</sup>, Sebastian Mella<sup>9</sup>, Shahragim Tajbakhsh<sup>1,2\*</sup>, Glenda Comai<sup>1,2\*</sup>

<sup>1</sup>Stem Cells & Development Unit, 25 rue du Dr. Roux, Institut Pasteur, 75015 Paris, France

<sup>2</sup>UMR CNRS 3738, Institut Pasteur, Paris, France

<sup>3</sup>Sorbonne Universités, Complexité du Vivant, F-75005, Paris, France

<sup>4</sup>Université Paris-Est, 77420, Champs-sur-Marne, France

<sup>5</sup>Freie Universität Berlin, 14195, Berlin, Germany

<sup>6</sup>Inserm, IMRB U955-E10, 94000, Créteil, France

<sup>7</sup>Institut Pasteur, Université Paris Cité, Image Analysis Hub, Paris, France

<sup>8</sup>Department of Developmental and Stem Cell Biology, Institut Pasteur, Université de Paris Cité, CNRS UMR 3738, 25 rue du Dr. Roux, 75015 Paris, France

<sup>9</sup>Hub de Bioinformatique et Biostatistique, Cytométrie et Biomarqueurs, Institut Pasteur, 75015 Paris, France

#First co-authors

‡Second co-authors

\*Co-corresponding authors

Keywords: muscle stem cell diversity, extraocular muscles, mesenchymal stromal cells, MuSC expansion, MuSC sc-RNAseq, matrisome, TF network

1 **Abstract**

2 Skeletal muscle stem cells (MuSC) are recognized as functionally heterogeneous. Cranial MuSCs are  
3 reported to have greater proliferative and regenerative capacity when compared to the ones in the limb.  
4 A comprehensive understanding of the mechanisms underlying this functional heterogeneity is lacking.  
5 Here we used clonal analysis, live imaging and scRNA-seq to identify critical features that distinguish  
6 extraocular (EOM) from limb muscle stem cell populations. A *Myogenin*<sup>tdTom</sup> reporter showed that the  
7 increased proliferation capacity of EOM MuSCs correlates with deferred differentiation and lower  
8 expression of the myogenic commitment gene *Myod*. Unexpectedly, *in vitro* activated EOM MuSCs  
9 expressed a large array of extracellular matrix components typical of mesenchymal non-muscle cells.  
10 Computational analysis underscored a distinct co-regulatory module, which is absent in limb MuSCs,  
11 as driver of these features. The EOM transcription factor network, with *Foxc1* as key player, appears to  
12 be hardwired to EOM identity as it persists during growth, disease, and *in vitro* after several passages.  
13 Our findings shed light on how high-performing MuSCs regulate myogenic commitment by remodeling  
14 of their local environment and adopting properties not generally associated with myogenic cells.  
15

## 16 INTRODUCTION

17 Genetic and transcriptomic studies have shown that the MuSC population in any particular anatomical  
18 location is heterogeneous. Certain subsets are more prone to self-renewal or differentiation, differ in  
19 transplantation efficiency, as well as their stem cell-niche interactions, metabolism, and resistance to  
20 stress upon activation (Barruet et al., 2020; Chakkalakal et al., 2014; Dell'Orso et al., 2019; Dumont et  
21 al., 2015; Gayraud-Morel et al., 2012; Hernando-Herraez et al., 2019; Micheli et al., 2020; Morree et al.,  
22 2019; Ono et al., 2012; Rocheteau et al., 2012; Scaramozza et al., 2019; Tierney et al., 2018; Vartanian  
23 et al., 2019; Yartseva et al., 2020; Yennek et al., 2014). Despite this diversity, MuSCs share common  
24 functions that are essential for growth and repair (Lepper, 2011; Murphy, 2011; Sambasivan, 2011).  
25 Myogenic commitment and differentiation involving *Myod* and *Myog*, respectively, occur in response to  
26 injury or growth factors in culture media following isolation of the *Pax7*-expressing MuSCs (Evano and  
27 Tajbakhsh, 2018; Zammit et al., 2004).

28 Unexpectedly, MuSCs in different anatomical locations were found to be programmed with distinct  
29 upstream transcription factors (TF) prior to acquiring myogenic identity (Gopalakrishnan et al., 2015;  
30 Harel et al., 2009; Kelly et al., 2004; Sambasivan et al., 2009; Tajbakhsh et al., 1997). Extraocular  
31 muscles (EOMs) are derived from unsegmented cranial mesoderm and are regulated by distinct  
32 transcription factors and signalling molecules compared to the somite-derived limb and trunk muscles  
33 (Grimaldi and Tajbakhsh, 2021; Michailovici et al., 2015; Sambasivan et al., 2011). For example, mice  
34 lacking the transcription factor *Pitx2* do not form EOMs whereas other cranial and somite derived  
35 muscles are unaffected (Diehl et al., 2006; Gage et al., 1999; Zacharias et al., 2011). As some muscle  
36 subsets, like the EOMs, are preferentially spared in muscular dystrophies and during ageing (Emery,  
37 2002; Formicola et al., 2014; Verma et al., 2017) and their MuSCs are functionally more robust in terms  
38 of proliferation and engraftment efficiency (Stuelsatz et al., 2015), intrinsic properties of MuSCs or  
39 myofibers might determine their differential sensitivity to disease (Randolph and Pavlath, 2015; Terry  
40 et al., 2018). Notably, single-cell transcriptomic analysis identified the thyroid hormone signalling  
41 pathway as a key factor preventing senescence entry of EOM MuSCs in dystrophin deficient (DMD) rats  
42 (Taglietti et al., 2023). Moreover, profiling of EOM MuSCs after heterotopic transplantation into limb  
43 muscle showed that, despite significant transcriptional changes, approximately 10% of EOM-specific  
44 genes persisted in the ectopic niche (Evano et al., 2020). This finding suggests that cell autonomous  
45 regulation of MuSC properties predominates to a certain extent in EOM. Yet, the existence of deeply-  
46 rooted TF gene regulatory networks within MuSC subsets and their role in maintaining anatomically  
47 distinct phenotypes remains largely unexplored.

48 Using droplet-based scRNA-seq, we investigated the transcriptional states that govern the  
49 outperformance of MuSC subsets. We identified key regulators that confer distinct mesenchymal-like  
50 features to activated EOM MuSCs, and extensive expression of extracellular matrix (ECM) components.  
51 Activated EOM MuSCs are less prone to differentiation and thus appear to be in a more stem-like state  
52 that is maintained *in vitro*, upon passages and *in vivo* during growth, through a specific set of co-  
53 regulated transcription factors.

## 54 RESULTS

### 55 Temporal heterogeneity in myogenic commitment to differentiation among MuSCs

56 We isolated EOM and *Tibialis anterior* (TA) MuSCs by FACS using *Tg:Pax7-nGFP* mice (Sambasivan  
57 et al., 2009) and plated them at the same density to follow up their proliferation and differentiation  
58 dynamics (**Figure 1A-B**). Quantification of the number of total and proliferative nuclei (5-Ethynyl-2'-  
59 deoxyuridine, EdU uptake, 2h pulse) at D3, D4 and D5 showed a 2.9 to 4.4-fold change increase in  
60 EOM compared to TA (**Figure 1C**). However, the percentage of total proliferative cells remained  
61 unchanged in both conditions at every time point (**Figure 1D**), arguing that the division probability is  
62 equal for EOM and TA. Yet, EOM cultures had twice the percentage of PAX7+ cells and less fusogenic  
63 myoblasts compared to TA at later timepoints (D10, **Figure 1E, F**).

64 We then performed clonal analysis of freshly isolated EOM MuSCs (**Suppl Figure 1A**) and showed that  
65 they displayed a 7-fold higher clonal capacity (mean 1315 cells/clone) compared to those from TA (186  
66 cells/clone) (**Suppl Figure 1B, T1**), in agreement with a previous study (Stuelsatz et al., 2015).  
67 Surprisingly, the higher clonogenic properties of EOM persisted even when they were pre-amplified for  
68 2 days *in vitro* where they yielded 3656 cells/clone compared to 297 cells/clone for TA (12-fold  
69 difference; **Suppl Figure 1B, T2**). Given that EOM and TA MuSCs exhibited a similar proliferative rate  
70 in bulk cultures, the clonal data suggests that the greater cellular output of EOM MuSCs is probably due  
71 to delayed differentiation. Since *Myog* expression is followed by cell-cycle withdrawal (Andrés and  
72 Walsh, 1996; Benavente-Diaz et al., 2021; Guo et al., 1995), a delay in its expression could allow for  
73 sustained expansion of EOM MuSCs.

74 To test this hypothesis, we assessed the differentiation dynamics of EOM and TA MuSCs *in vitro* by live  
75 imaging using the *Tg:Pax7-nGFP;Myog<sup>ntdTom</sup>* mouse line (Benavente-Diaz et al., 2021; Sambasivan et  
76 al., 2009), which allowed simultaneous isolation of MuSCs and monitoring of the onset of *Myog*  
77 expression by a nuclear tdTOMATO (tdTOM) reporter. Myogenic cells were tracked continuously from  
78 D3 and tdTOM intensity scored (**Figure 1G**). TA myogenic cells initiated reporter gene expression earlier  
79 than EOM cells (**Figure 1H**). The percentage of tdTOM+ cells sharply increased in the TA from 5% at  
80 80h (D3+8hours) post-plating to 40% at 96h (D4). Significantly, only ~7% of EOM cells were tdTOM+ by  
81 96h *in vitro* (**Figure 1I**). Western Blot (**Suppl Figure 1C, D**) data were in agreement with the live imaging  
82 analysis. For instance, expression of the cell cycle inhibitor *p21*, which regulates cell cycle exit (Guo et  
83 al., 1995; Zhang et al., 1999), and expression of phosphorylated p38, which promotes MEF2  
84 transcriptional activity to initiate differentiation (Rugowska et al., 2021), were significantly downregulated  
85 in activated EOM MuSCs compared to TA. RT-qPCR showed higher levels of *Myogenin* and *p21*  
86 transcripts in TA compared to EOM MuSCs already at D2 (**Figure 1J**). As such, this data suggests that  
87 EOM progenitors are less prone to myogenic commitment.

88 Finally, to test if EOM cells have a global impairment in myogenic differentiation, we used the *Tg:Pax7-*  
89 *nGFP;Myog<sup>ntdTom</sup>* mice to isolate the stem (PAX7+/GFP+) and committed (MYOG+/tdTOM+) fractions

90 after D5 *in vitro* (**Figure 1K, Suppl Figure 1E**). No differences were seen by RT-qPCR among EOM  
91 and TA tdTOM+ cells for *Myod*, *Myogenin*, the fusogenic markers *Myomixer* and *Myomaker* (Sampath  
92 et al., 2018) and embryonic myosin heavy chain (*Myh3*) indicating that differentiation of EOM cells was  
93 not generally impeded (**Figure 1L**). However, plating EOM and TA tdTOM+ myoblasts at high density  
94 in differentiation media revealed a lower fusion index and higher percentage of EOM myoblasts  
95 incorporating EdU on their last division (**Suppl Figure 1F-H**, (Benavente-Diaz et al., 2021)). Therefore,  
96 a general delay in the differentiation of EOM MuSCs appears to contribute to the higher number of  
97 myogenic cells (**Suppl Figure 1I**).

## 98 **Distinct signature of EOM MuSCs upon activation**

99 To understand the phenotypic differences between EOM and TA MuSCs, we performed scRNA-seq of  
100 *in vitro* activated MuSCs using the 10x Chromium (**Figure 2A**). Unsupervised clustering divided cells  
101 into 2 clusters per sample (**Figure 2B**) that were annotated as progenitors (Prog) or differentiating (Diff)  
102 based on myogenic marker expression (**Figure 2B, C**). Notably, EOM progenitors exhibited reduced  
103 expression of *Myod* RNA and protein across the entire population at D3 and D5 *in vitro*, thereby  
104 suggesting a lower propensity to differentiate (**Figure 2B, Suppl Figure 2A**).

105 Analysis of differentially expressed genes (DEGs) showed that each cell state had a distinct  
106 transcriptional pattern (**Figure 2D, Suppl Table 1**). As expected, TA progenitors expressed a defined  
107 Hox-signature (Evano et al., 2020) and inhibitors of differentiation (Id1, Id2, (Jen et al., 1992; Kumar et  
108 al., 2009)). EOM and TA differentiating cells shared part of their signature (*Myog*, *Mymx*, *Myl4*).  
109 However, EOM progenitors displayed markers not been previously noted in MuSCs, such as *Mgp*, *Bgn*,  
110 *Col1A2* and *Acta2* (smooth muscle actin) (**Figure 2D**).

111 We then performed reactome analysis of DEGs (**Figure 2E, Suppl Figure 2B, Suppl Table 2**). As  
112 suggested by the DEG heatmap, TA progenitors shared common pathways with the differentiating  
113 clusters. Multiple pathways involved in ECM organisation characterised EOM progenitors including  
114 “ECM proteoglycans”, “crosslinking of collagen fibrils” and “integrin cell surface interactions”. EOM  
115 progenitors were also specifically enriched in Pdgfr $\beta$ , a receptor for platelet-derived growth factor, and  
116 proteins related to insulin like growth factor binding and integrin signaling (**Figure 2F, Suppl Figure 2C,**  
117 **Suppl Table 3**). Thus, these analyses uncovered a non-canonical signature in EOM progenitors upon  
118 activation.

## 119 **Closer molecular overlap of EOM MuSCs across cell states**

120 We then compared the signature of EOM and TA myogenic progenitors *in vitro* with the quiescent  
121 counterparts *in vivo* by scRNA-seq immediately after isolation by FACS (**Figure 3A, B**). While both  
122 populations displayed consistent expression of MuSC markers, *Myod* expression was restricted to TA  
123 MuSCs (**Figure 3C, D**), suggesting an earlier activation in response to the isolation procedure (Brink et  
124 al., 2017; Machado et al., 2017; Velthoven et al., 2017). Differentiation markers like *Myog* were absent

125 in both populations (**Figure 3C, D**). Visualization of the top 25 most variably expressed genes  
126 highlighted distinct transcriptional programs of EOM and TA quiescent clusters (**Figure 3E, Suppl Table**  
127 **4**). Moreover, microarray analysis showed that EOM quiescent MuSCs also stand apart from those in  
128 other cranial-mesoderm derived muscles, such as the esophagus and masseter (**Suppl Figure 3A**).

129 Interestingly, we found several conserved genes between the quiescent and activated sc-RNAseq  
130 states at each anatomical location, while others were unique to the quiescent or activated cell states  
131 (**Figure 3F-I**). EOM genes unique to the quiescent state included *Tshr*, encoding the thyroid-stimulating  
132 hormone receptor, previously recognized in bulk RNAseq as “EOM-resistant”, i.e. retained following  
133 engraftment into the limb (Evano et al., 2020), and shown to prevent senescence in EOM MuSCs of  
134 DMD rats (Taglietti et al., 2023). Matrix Gla protein (*Mgp*), a critical regulator of angiogenesis in multiple  
135 organs (Kida and Yamaguchi, 2022), was exclusively upregulated in EOM cells upon activation (**Figure**  
136 **3H**). Amongst the conserved EOM genes across cell states we identified *Pitx2*, a major upstream  
137 regulator of EOM development (Gage et al., 1999), *Fos*, which labels a subset of limb MuSCs with  
138 enhanced regenerative capacity (Almada et al., 2021) and *Foxc1*, which is involved in ocular  
139 development (Smith et al., 2000) and reported to regulate the balance between myogenic and vascular  
140 lineages within somites (Lagha et al., 2009; Mayeuf-Louchart et al., 2016) (**Suppl Figure 3B**). The EOM  
141 signature also featured *Igf1bp7*, a specific marker of quiescent MuSCs (Fukada et al., 2007) that is  
142 upregulated upon exercise (Chen et al., 2020) (**Figure 3F, Suppl Figure 3B, C**). Additionally, the EOM  
143 common signature encompassed several ECM components and regulators (e.g. *Bgn*, *Loxl1*, *Col1a2*,  
144 *Col6a1*), TFs associated with fibrosis and connective tissue development (e.g. *Foxp1* (Grimaldi et al.,  
145 2022; Shao and Wei, 2018), *Egr1* (Havis and Duprez, 2020)) and *Acta2* (alpha smooth muscle actin), a  
146 marker of smooth muscle, fibroadipogenic progenitors (Joe et al., 2010; Uezumi et al., 2010) and smooth  
147 muscle-mesenchymal cells (SMMCs, (Giordani et al., 2019)) (**Figure 3F, H**).

148 In the TA, *Lbx1*, *Vgll2* and *Hox* genes were found as common signature throughout cell states (**Figure**  
149 **3G,I; Suppl Figure 3B, C**). *Lbx1* is a homeobox transcription factor required for the migration of  
150 myogenic progenitor cells to the limbs (Brohmann et al., 2000; Gross et al., 2000) and *Vgll2* (previously  
151 Vito-1) is a key cofactor of the myogenic differentiation program (Günther et al., 2004; Maeda et al.,  
152 2002). *Lbx1*, *Vgll2* and several *Hox* genes had been already identified in the limb both at the MuSC level  
153 and in entire muscles in the adult (Evano et al., 2020; Honda et al., 2017; Terry et al., 2018) (**Figure 3I**).

154 Altogether, our analysis revealed a closer molecular overlap for EOM MuSCs across cell states  
155 (quiescence vs *in vitro* activation), including several TFs and ECM markers that were distinct from TA  
156 MuSCs.

### 157 **Activation of EOM MuSCs involves extensive ECM remodelling**

158 Given the well-established role of ECM synthesis and remodelling on MuSC proliferation and self-  
159 renewal (Baghdadi et al., 2018; Rayagiri et al., 2018; Tierney et al., 2016; Yin et al., 2013), we examined  
160 these features using Matrisome database (Matrisome DB), which compiles *in silico* and experimental

161 data on ECM constituents (Naba et al., 2015). We identified components of the Matrisome DB present  
162 in our single-cell dataset and created a global score for ECM component expression (**Figure 4A**) (see  
163 Methods). Significantly, the EOM progenitor cluster had the highest matrisome score (**Figure 4A**) and  
164 expressed the highest number of genes for each matrisome category (**Figure 4B**).

165 We then validated some matrisome candidate genes by immunofluorescence or Western blot on *in vitro*  
166 activated EOM and TA MuSCs (**Figure 4C-D**). EOM progenitors expressed higher levels of Fibronectin  
167 (FN1), which promotes MuSC expansion in a cell autonomous manner (Bentzinger et al., 2013),  
168 Collagen I (COL1), a major component of the fibrotic ECM (Dulauroy et al., 2012) shown to suppress  
169 differentiation of C2C12 cells (Alexakis et al., 2007) and Collagen IV (COL4), which is secreted by  
170 MuSCs as well as myoblasts and fibroblasts in culture (Baghdadi et al., 2018; Köhl et al., 1984) (**Figure**  
171 **4C**). In addition, EOM progenitors also displayed differential expression of PDGFR $\beta$ , a gene identified  
172 on the EOM molecular functions (**Suppl Figure 2C**). PDGFR $\beta$  is a tyrosine-kinase receptor commonly  
173 expressed by mesenchymal cells and pericytes (Hellström et al., 1999; Levéen et al., 1994; Soriano,  
174 1994) (**Figure 4C**). Interestingly, Pdgfr $\beta$  and Acta2 are markers of Smooth Muscle-Mesenchymal Cells  
175 (SMMCs), a novel Itga7+ Vcam- Pdgfr $\beta$ + Acta2+ cell subpopulation present in adult muscle that exhibits  
176 myogenic potential and promotes MuSC engraftment following transplantation (Giordani et al., 2019).

177 Western blot analysis confirmed that EOM progenitors produce higher levels of Caveolin1 (CAV1) and  
178 CAVIN1 (**Figure 4D**), which are co-expressed in caveolae and downregulated upon differentiation of  
179 rhabdomyosarcoma cells (Faggi et al., 2015). CAV1 is a marker of quiescent and Pax7+ activated  
180 mouse MuSCs (Gnocchi et al., 2009) whereas in human, CAV1+ MuSCs are associated with ECM  
181 organization, expression of quiescent markers, and increased engraftment capacity (Barruet et al.,  
182 2020). SPARC, MGP and IGFBP7 were also upregulated in EOM activated MuSCs (**Figure 4D**). Their  
183 activity appears to be context dependent as they promote or suppress proliferation in different cell types  
184 (Ahmad et al., 2017; Artico et al., 2021; Cho et al., 2000; Jing et al., 2019; Li et al., 2020; Melouane et  
185 al., 2018). Given the large number of matrisome genes characterising EOM progenitors, we examined  
186 the expression of MMP2, a matrix remodelling protein (Gonçalves et al., 2022) whose activation  
187 increases the proportion and mobility of Pax7+ cells (Mu et al., 2010). As expected, an enrichment of  
188 the active form of MMP2 was observed in EOM progenitors. TA progenitors displayed instead an  
189 enrichment of the pro-MMP2 or latent form (**Figure 4D**).

190 In parallel, we assessed to what extent activated EOM MuSCs resemble other cells in skeletal muscle  
191 displaying mesenchymal features (**Suppl Figure 4A, Suppl Table 5**). Notably, EOM progenitors  
192 displayed a higher score for SMMCs (Giordani et al., 2019), FAPs (Oprescu et al., 2020), myotendinous  
193 junction B myonuclei (Kim et al., 2020), Twist2+ cells (Liu et al., 2017), fetal MuSCs (Tierney et al.,  
194 2016), developing limb connective tissues (Lima et al., 2021) and the skeletal muscle mesenchyme  
195 subpopulation identified in human fetal limb (Xi et al., 2020). In contrast, TA progenitors displayed a  
196 higher score for myogenic commitment and differentiation (**Suppl Figure 4A**).



197 Finally, we focused on PDGFR $\beta$ , for which FACS antibodies exist, to validate the potential link between  
198 mesenchymal EOM features and *in vitro* expansion capacity. Flow cytometry analysis corroborated the  
199 scRNA-seq and immunofluorescence data, where PDGFR $\beta$  was enriched in EOM samples (**Suppl**  
200 **Figure 4B, C**). To distinguish the functional properties of PDGFR $\beta^+$  and PDGFR $\beta^-$  cells, we pulsed  
201 them with EdU (**Figure 4G**). Notably, PDGFR $\beta^+$  cells had a significantly higher proliferative capacity  
202 (**Figure 4H-J**). While the percentage of MYOD $^+$  cells was unchanged between the two cell populations,  
203 MYOG was much more abundant in the PDGFR $\beta^-$  fraction (**Figure 4K, L**). Therefore, the PDGFR $\beta^+$   
204 myoblasts are characterised by a higher proliferative potential and decreased differentiation status.  
205 Altogether, our analysis showed that EOM progenitors have an unusual transcriptome profile, express  
206 a wide range of ECM-related factors, and harbour a mesenchymal signature.

### 207 **EOM transcriptome profile is associated with a unique transcription factor network**

208 To further investigate myoblast heterogeneity, we inferred single cell regulatory networks using  
209 pySCENIC (Aibar et al., 2017; Sande et al., 2020) where co-expression patterns and transcription factor  
210 binding motifs identify "regulons" (transcription factors and putative targets) (**Figure 5A, Suppl Table**  
211 **6**). As expected, regulons associated with myoblast differentiation such as *Myod*, *Myog* and *Mef2* family  
212 were specifically active in differentiated cells of EOM and TA (**Figure 5B**). Of note, the top 5 regulons  
213 of TA progenitors were also found to be active in EOM progenitors, whereas the top 5 regulons of EOM  
214 progenitors were unique to this cluster (**Figure 5B**). EOM progenitors displayed unique regulons  
215 involved in connective tissue and ECM remodelling including *Egr1* (Havis and Duprez, 2020) and  
216 *Creb3l1*, a downstream effector of thyroid hormone signaling (García et al., 2017; Sampieri et al., 2019).  
217 Top regulons of EOM progenitors are also involved in cell proliferation (*Foxc1* (Yang et al., 2017), *Sox4*  
218 (Moreno, 2019), *Fos* (Almada et al., 2021), *Klf6* (Dionyssiou et al., 2013), *Ebf1* (Györy et al., 2012)),  
219 commitment into endothelial and smooth muscle fates (*Foxc1* (Han et al., 2017; Mayeuf-Louchart et al.,  
220 2016; Whitesell et al., 2019; Yang et al., 2017)) as well as differentiation into mesenchymal lineages  
221 (*Ebf1*, (El-Magd et al., 2021; Jimenez et al., 2007; Pagani et al., 2021). Of note, some EOM regulons  
222 were already enriched in quiescent EOM MuSCs, and their expression was upregulated upon activation  
223 (**Suppl Figure 5A, B**).

224 We then built a network restricted to transcription factors (**Figure 5C**), where each node (circle) is an  
225 active transcription factor and each edge (distance between nodes) is an inferred regulation between 2  
226 transcription factors (Grimaldi et al., 2022). When placed in a force-directed environment (see Methods),  
227 these nodes aggregated based on the number of shared edges thereby highlighting associated and co-  
228 regulating transcription factor modules. Strikingly, the transcription factors of the most specific regulons  
229 of each cluster preferentially organised as tightly related modules (**Figure 5C**). In agreement with our  
230 previous analyses, known co-regulating transcription factors in differentiated cells (*Myod*, *Myog*, *Mef2a*,  
231 *Mef2c*, *Myf6*) formed a tight module (**Figure 5C**). The TA module was composed of genes required for  
232 limb embryonic development (*Hox* genes, *Lbx1*) (Gross et al., 2000; Swinehart et al., 2013), where  
233 *Hoxa11*, is a determinant of embryonic limb identity (Zakany and Duboule, 2007), and *HoxA* and *HoxC*

234 clusters are signatures of adult TA MuSCs (Evano et al., 2020; Yoshioka et al., 2021) (**Figure 5C, Suppl**  
235 **Figure 5B**).

236 The EOM module included *Foxc1*, *Egr1*, *Creb3l1*, *Dmrta2*, *Sox4*, *Fos* and *Egr1* together with *Pax7* and  
237 *Hes1* which support MuSC quiescence (Baghdadi et al., 2018; Mourikis et al., 2012; Olguin and Olwin,  
238 2004; Relaix and Zammit, 2012). However, this network persists in proliferating EOM progenitors as  
239 assessed by the higher levels of PAX7, CCND1 (Cyclin D1), together with EOM TFs (FOXC1, EBF1  
240 and CREB3L1) at the protein level (**Suppl Figure 5C, D**). Although *Fos* and *Egr1* act as stress  
241 signatures following tissue dissociation (Machado et al., 2021) in our dataset, the expression of these  
242 genes (i.e. the StressIndex) correlated with *Pax7* expression and anti-correlated with *Myod* (**Suppl**  
243 **Figure 5E, F**). Regression of the StressIndex or removal of these genes did not alter the general aspect  
244 of the data (**Suppl Figure 5G**), pointing at a role for these genes also in the EOM progenitor  
245 maintenance.

#### 246 **EOM features are present during the growth phase *in vivo* and retained upon passages *in vitro***

247 Given that EOM MuSCs possess an unusual transcriptomic state and delayed myogenic commitment,  
248 we examined these features following passage of MuSCs isolated from *Tg:Pax7-nGFP;Myog<sup>ntdTom</sup>* *in*  
249 *vitro* (**Figure 6A, Suppl Figure 6A, B**). While the total cell number was reduced with passages for both  
250 EOM and TA (**Suppl Fig 6A, B**), the normalised cellular output was consistently higher for the EOM and  
251 correlated with a lower tdTOM/GFP ratio (**Figure 6B, C**). Real-time qPCR and protein analysis showed  
252 that expression of *Pax7* and *Hey1*, a bHLH transcription factor that is required for MuSC maintenance  
253 (Noguchi et al., 2019), EOM specific regulon TFs (*Foxc1*, *Sox4*, *Ebf1*, *Creb3l1*) and genes identified by  
254 the matrisome or molecular functions (*Bgn*, *Sparc*, *Igfbp2*, *Igfbp7*, *Pdgfrb*) were all retained or even  
255 increased in whole EOM cell populations (mix of GFP+ and tdTOM+ cells) after several passages  
256 (Figure 6D-G), and specifically in the GFP+ fraction (**Suppl Figure 6C-E**). These results show that EOM  
257 MuSCs cells retain a cell autonomous non-canonical signature that is hard-wired even after extended  
258 cell culture and that is not present in the TA.

259

260 Next, we assessed whether EOM progenitor features were already present in their activated state *in*  
261 *vivo*, for instance, in fetal development and postnatal stages, where extensive muscle growth and  
262 myogenic cell expansion occurs (Gattazzo et al., 2020a; Relaix and Zammit, 2012) or if these features  
263 were only acquired in adulthood upon reactivation from the quiescent state *in vitro*. First, we isolated  
264 EOM and TA MuSCs at E18.5 and P21 and showed that here too, EOM cells were less differentiated  
265 upon activation *in vitro* (**Suppl Figure 7A**). Then, we examined activated MuSCs directly *in vivo* by RT-  
266 qPCR. Given that GFP protein persists during myogenic commitment (Sambasivan et al., 2009) and this  
267 might introduce a bias in the initial populations, we isolated by GFP+/tdTOM- fractions from *Tg:Pax7-*  
268 *nGFP;Myog<sup>ntdTom</sup>* mice at P7-P10 (**Figure 7A, Suppl Figure 7B**). Similarly, to the *in vitro* sc-RNAseq  
269 data, RT-qPCR revealed significantly lower levels of *Myogenin* and higher transcript levels for EOM  
270 specific regulon TFs (*Foxc1*, *Ebf1*, *Sox4*, *Creb3l1*) and matrisome components on the activated EOM  
271 progenitors (**Figure 7B**). Together with our live-imaging (Figure 1G-I), FACS (Suppl Figure 1E) and sc-

272 RNAseq data (Figure 2), this analysis suggests that EOM MuSCs repress myogenic commitment and  
273 appear to maintain a more "stem-like" state upon activation, and this property is conserved from  
274 development to adulthood.

### 275 **Foxc1 marks the EOM MuSC lineage and plays a role in progenitor cell maintenance**

276 We then focused on *Foxc1* for further analysis as it is one of the top regulons and DEG of the activated  
277 and quiescent sc-RNAseq dataset (**Figure 5 A, B, Suppl Figure 3B, Suppl Figure 5B, D**) and we  
278 previously identified *Foxc1* as a DEG and top regulon of EOM progenitors in the early embryo  
279 (E11.5,(Grimaldi et al., 2022)). Notably, bulk RNAseq (Terry et al., 2018) also showed higher *Foxc1*  
280 expression in entire EOMs compared to other adult muscle groups (**Suppl Fig 7C**). As such, *Foxc1* is  
281 a good candidate for determining EOM properties throughout the myogenic lineage continuum and  
282 across developmental states.

283 First, we validated FOXC1 protein expression *in vivo* and *in vitro*. As expected, immunostaining on tissue  
284 sections of E12.5 *Myf5<sup>Cre</sup>;R26<sup>tdTom</sup>* embryos showed expression of FOXC1 in 54.7% of EOM myogenic  
285 progenitors but not in limb, back, nor masseter muscles (**Suppl Figure 7D, E**). Analysis of  
286 *Pax7<sup>CreERT2</sup>;R26<sup>tdTom</sup>* mice showed FOXC1 expression in postnatal (P10) and adult EOM MuSCs (**Figure**  
287 **7C-E**) but not in the TA muscles. FOXC1 was strongly expressed in adult EOM MuSC cultures (**Suppl**  
288 **Figure 7F-H**). FOXC1 was expressed in about 75% of PAX7+ cells at D5, expression was progressively  
289 lost during differentiation and the majority of the FOXC1+ cells incorporated EdU at every time point  
290 (**Suppl Figure 7I, J**). Thus, differences in *Foxc1* expression between the EOM and TA appear to arise  
291 during development and persist upon activation.

292 As differences in *Myogenin* mRNA between EOM and TA were already evident at D2 following *in vitro*  
293 activation (**Figure 1J**), we used this early timepoint to functionally validate a potential role for *Foxc1* in  
294 progenitor maintenance. Thus, we silenced *Foxc1* using siRNA in EOM MuSCs right after FACS (**Suppl**  
295 **Figure 7K**). The total cell number and percentage of PAX7+ cells were not changed 2 days after  
296 silencing, despite effective downregulation of FOXC1 at the protein level (**Suppl Figure 7L-L'**) and  
297 transcript level (**Suppl Figure 7M**). Yet, a 2.7-fold increase in *Myogenin* expression was detected by  
298 RT-qPCR following silencing (**Suppl Figure 7M'**). Given that the effect of siRNAs was only transient,  
299 we transduced EOM activated MuSCs with lentiviruses expressing different short-hairpin RNAs (shRNA)  
300 against *Foxc1* to be able to examine later timepoints (**Suppl Figure 7N**). Immunofluorescence and EdU  
301 uptake at D5 showed an efficient depletion of FOXC1 protein, and concomitant severe reduction in the  
302 total cell number and percentage of EdU+ cells (**Suppl Figure 7O-P**). While lower number of myotubes  
303 were formed in shRNA FOXC1 TA cells, the fusion index was not significantly different (**Suppl Figure**  
304 **7Q, R**).

305

306 To assess if *Foxc1* would confer some EOM features to TA, we overexpressed this gene in activated  
307 TA MuSCs cells (**Figure 7F**) using gain-of-function (GOF) FOXC1 lentiviruses carrying mCherry as  
308 reporter that allow to re-isolate the transduced cells (**Figure 7G, H**). Notably, there was robust

309 upregulation of FOXC1 (15-30x) at D5 (**Figure 7I, J, K', N**) and many *Foxc1* direct targets (**Suppl Table**  
310 **7**), including matrisome components (e.g. *Sparc*, *Pdgfrβ*, *Fbn1*) and other EOM specific regulon TFs  
311 (e.g. *Ebf1*, *Creb3l1*, *Egr1*). Properties of re-isolated GOF cells (**Figure 7K-Q**) included a larger cellular  
312 and nuclear area (**Figure 7K, K', O**) and less fusogenic potential (**Figure 7L, M**). Unexpectedly, FOXC1  
313 overexpression also resulted in downregulation of *Pax7* and *Myod*, less cells/well and reduced EdU  
314 uptake (**Figure 7J, P, Q**). These phenotypes might be the result of strong overexpression and cells  
315 acquiring a strong mesenchymal character. We thus investigated the FOXC1 GOF condition in “mixed  
316 cultures” which contain transduced (FOXC1+mCherry+) and non-transduced (FOXC1-mCherry-) TA  
317 cells (**Figure 7F, R-Y**). This strategy allowed us to assess the effect of secreted factors produced by  
318 FOXC1+ cells on non-transduced cells. As expected for mixed cultures, FOXC1 fluorescence intensity  
319 showed a bimodal distribution, with one population being as negative control and the other expressing  
320 high levels of the protein (**Figure 7R**). Interestingly, the total number of nuclei in the mixed GOF wells  
321 was higher than controls (**Figure 7T**), which contrasts with the result in pure GOF cultures (**Figure 7P**).  
322 Thus, we evaluated the individual cellular properties of transduced and non transduced cells in the  
323 mixed GOF cultures. While FOXC1+ cells showed higher nuclear area and reduced EdU uptake as in  
324 pure GOF cultures, overexpression of FOXC1 led to an augmentation in both the number and  
325 percentage of proliferating cells within the non-transduced population (compare FOXC1+/-  
326 subpopulations in **Figure 7S, U** with **Figure 7O, Q**).

327  
328 Finally, we performed live imaging on FOXC1 GOF mixed cultures (**Figure 7F**). While starting with  
329 control and GOF cultures with similar transduction efficiencies (88% and 80% mCherry+ cells at 12h,  
330 respectively) (**Figure 7V**), we found that the density of mCherry+ cells in GOF wells was reduced by  
331 half of that of control wells by 48h (**Figure 7X, Movie 1 and 2**), with a concomitant increase in the density  
332 of mCherry- cells (**Figure 7Y, Movie 1 and 2**).

333 Therefore, our data suggest a role for the FOXC1-induced secretome in cell proliferation of adjacent  
334 cells (**Figure 7Z**). Importantly, overexpression of *Creb3l1*, another EOM regulon TF, in TA MuSCs  
335 (**Suppl Figure 7S**) did not show alterations in *Pax7*, *Myod*, most matrisome genes examined, nor the  
336 cellular properties (**Suppl Figure 7S-Z**). Altogether, our findings support the notion that physiological  
337 levels of *Foxc1* in EOM MuSCs may allow their maintenance in a progenitor like state, likely through  
338 secreted factors.

### 339 **Transcription dynamics expose EOM and TA disparities in progenitor-state maintenance**

340 We then performed more detailed bioinformatic analysis of the matrisome by correlating the number of  
341 matrisome-driving regulons between EOM and TA upon activation (**Figure 8A-C, Suppl Table 8**). EOM  
342 MuSCs consistently regulated a higher number of matrisome genes than TA cells (**Figure 8A**). The ratio  
343 of the number of regulations of matrisome genes between EOM and TA activated MuSCs showed that  
344 the difference was maximal when considering the top 5 regulons, including as expected *Foxc1* together  
345 with *Alx4*, *Dmrta2*, *Zmiz1* and *Fos* (**Figure 8B, C**). Interestingly, *Foxc1*, *Dmrta2* and *Fos* were also active  
346 regulons in quiescence, with slight disparities between EOM and TA (**Suppl Table 9**).

347 Next, we set out to determine whether matrix genes underlie the transition towards progenitors and  
348 committed cells during activation using scVelo (Bergen et al., 2020). This method computes local  
349 changes in the relative number of unspliced/spliced variants (Manno et al., 2018) and identifies  
350 candidate "driver genes", i.e. most transcriptionally dynamic and responsible for the inferred velocity  
351 (**Figure 8D, E**). Two distinct velocity streams stood out in both datasets, towards differentiation  
352 (*Myog*<sup>High</sup>) and towards a progenitor-state (*Pax7*<sup>High</sup>). Strikingly, a larger fraction of EOM cells appeared  
353 to transition towards a progenitor state compared to TA (**Figure 8D, E**). These trajectories did not appear  
354 to be specifically correlated with cell cycle phases (**Suppl Figure 8 A, B**), which was shown to influence  
355 transcriptomic data in some cases (McDavid et al., 2016). Hence, the velocity streams observed are  
356 most likely reflect transitions between distinct cell states instead of the cell cycle progression of a  
357 homogeneous cell state.

358 Using scVelo built-in functions, we extracted the top driver genes underlying the velocity towards the  
359 progenitor state in both datasets (**Figure 8F-G, Suppl Table 10, 11**). Out of the top 100 driver genes,  
360 30 were common to both datasets, including *Col5a1*, which plays a critical role in maintenance of  
361 quiescence (Baghdadi et al., 2018) (**Figure 8F,G**). Interestingly, several matrisome components  
362 including *, other collagens, and *Igfbp7* (Insulin growth factor binding protein 7), were unique to EOM.  
363 Of note, IGFs bind and regulate insulin-like growth factors (IGFs) thereby repressing myogenic  
364 differentiation but they also have IGF-independent activity (Clemmons, 1997; Engert et al., 1996; Jin et  
365 al., 2020). GO molecular functions associated with these driver genes during myogenic progenitor  
366 maintenance showed that this transition was characterised by active upregulation of ECM components  
367 specifically in EOM, in agreement with our previous results (**Suppl Figure 8C**).*

368 We then performed conditioned media (CM) exchange experiments to gain functional insights into the  
369 role of EOM secreted factors by culturing hindlimb cells in presence of EOM-CM, TA-CM or control  
370 media for 3 days (**Figure 8H**). In agreement with the FOXC1 GOF experiments (**Figure 7R-Z**) EOM-CM  
371 induced a ~5x increase in the total number of nuclei/well, whereas no significant differences were  
372 observed with TA-CM and control media (**Figure 8I**). Further, the percentage of EdU+ cells remained  
373 unchanged (**Figure 8J**) suggesting that EOM secreted factors may delay differentiation.

374 To assess if mesenchymal features of EOM cells were recapitulated *in vivo*, we asked whether bipotent  
375 myogenic progenitors that we previously identified in EOM to give rise to myogenic and connective  
376 tissue cells during embryogenesis (Grimaldi et al., 2022) persisted postnatally. Examination of  
377 *Myf5<sup>nlacZ</sup>;Pdgfra<sup>H2BGFP</sup>* mice, where *Myf5<sup>nlacZ</sup>* allows tracing myogenic progenitors and progeny, and GFP  
378 labels mesenchymal connective tissue cells, confirmed the presence of  $\beta$ gal+/GFP+ cells in the EOM  
379 but not in masseter and tongue muscles in the head (**Figure 8K, L**). Surprisingly, analysis of EOM and  
380 TA MuSCs and fibroadipogenic cells (FAPs) identified a hybrid population positive for both Sca-1 (FAPS  
381 marker, (Joe et al., 2010)) and GFP, only in EOM samples (8% of total GFP+ population; **Suppl Figure**  
382 **8D-F**). We then isolated FAPS, MuSCs, and the SCA-1+GFP+ cells from the EOM, and performed RT-  
383 qPCR, for *Pdgfra*, *Pdgfrb* and *Col1a2* (**Suppl Figure 8G**). Notably, the Sca-1+GFP+ progenitor  
384 population showed an intermediate pattern of expression of these matrisome genes between that of

385 MuSCs and FAPS, suggesting a mesenchymal signature that exclusively belongs to EOM MuSCs  
386 subsets. Finally, differential gene expression analysis of a publicly available sc-RNAseq dataset filtering  
387 on our EOM-specific regulon TFs, highlighted *Egr1* and *Foxc1* as upregulated in dystrophic EOM (**Suppl**  
388 **Figure 8H**), a condition where EOM MuSCs were described to be proliferative (Taglietti et al., 2023).  
389 Altogether, this *in vivo* data corroborated the results obtained by bioinformatic analysis on our *in vitro*  
390 activated MuSC dataset.

## 391 **DISCUSSION**

392 An unusual feature of skeletal muscle stem cells is their reliance on distinct gene regulatory networks  
393 (GRNs) in different anatomical locations. Most studies on myogenesis have focused on trunk and limb  
394 muscles and only a handful of transcription factors and signalling pathways have been identified as  
395 hallmarks of specific muscle groups. Here, we used multiple approaches and identify unusual features  
396 and specific GRNs that functionally distinguish EOM from TA MuSCs.

### 397 **EOM MuSCs are more refractory to *in vitro* differentiation**

398 By monitoring *Myog* and *Myod* expression, we showed that EOM MuSCs have a lower propensity to  
399 differentiate following activation and persist as a proliferative population. Given the pivotal role of *Myod*  
400 in commitment and differentiation (Vicente-García et al., 2022), the lower levels of *Myod* transcript and  
401 protein in activated EOM MuSCs even upon upregulation of the *Myog<sup>tdTom</sup>* reporter is intriguing and  
402 deserves further investigation. As foetal and early postnatal EOM MuSCs are also refractory to  
403 differentiation, we propose that this property might be hardwired by unique GRNs that are retained  
404 throughout development and adulthood. Notably, trunk foetal MuSCs were shown to be more resistant  
405 to myogenic progression upon *in vitro* expansion and contribute more efficiently upon transplantation than  
406 the adult counterparts (Sakai et al., 2013; Tierney et al., 2016). In addition, limb MuSCs cells isolated at  
407 birth displayed prolonged expansion and delayed fusion compared with those in the adult (Gattazzo et  
408 al., 2020b). Similarly, EOM MuSCs showed a reduced fusion index compared to those in adult limb.  
409 Altogether our data suggest that EOM MuSCs retain features of respective foetal and neonatal  
410 myogenic cells.

411 Major obstacles for cell-based therapies are the large cell numbers required for transplantation and the  
412 fact that *ex vivo* amplification of somite-derived MuSCs leads to a drastic decline in regenerative  
413 potential due to commitment to differentiation (Briggs and Morgan, 2013; Ikemoto et al., 2007; Montarras  
414 et al., 2005). While significant progress has been made (Charville et al., 2015; Ishii et al., 2018; L'honoré  
415 et al., 2018; Xie et al., 2021), the identification of factors that regulate cell fate decisions in distinct MuSC  
416 populations is another resource for advancing knowledge in this context.

### 417 **EOM progenitors exhibit a mesenchymal genetic signature upon activation**

418 scRNA-seq analyses provided some insights into the transcriptional landscape regulating MuSC  
419 quiescence, activation and self-renewal in somite-derived muscles (Dell'Orso et al., 2019; Hernando-

420 Herraiez et al., 2019; Machado et al., 2021; Micheli et al., 2020; Yartseva et al., 2020). For cranial  
421 MuSCs, our scRNA-seq analysis of activated EOM and TA MuSCs showed distinct transcriptional  
422 profiles that divided myoblasts into two subpopulations: those that resembled progenitors and those  
423 differentiating. The EOM progenitor population was characterised by higher *Pax7*, reminiscent of *in vitro*  
424 reserve cells (Laumonier et al., 2017; Yoshida et al., 1998; Zammit et al., 2004) and ontology analysis  
425 of its DEGs showed an enrichment in ECM organisation processes and *Pdgf* signalling.

426 Transcriptomic analysis of trunk MuSCs highlighted a dynamic profile of *Pdgf* ligands and receptors  
427 during myogenesis (Contreras et al., 2021). Treatment with NOTCH and PDGFR $\beta$  ligands (DLL4 and  
428 PDGF-BB respectively) enhanced migration, expression of stem cell markers and perivascular-like  
429 features in MuSCs (Gerli et al., 2019) and embryonic myoblasts (Cappellari et al., 2013). Notably also,  
430 heterogeneity of activated MuSCs was noted during regeneration, including a transitional Notch2-high  
431 state and an ECM-high state that regulates self-renewal (Yartseva et al., 2020). As PDGFR $\beta$  and several  
432 Notch pathway components (e.g. Notch1, Notch3, Hey1) are co-expressed in activated EOM  
433 progenitors, and at significantly higher levels than in TA muscle, we speculate that cross-talk between  
434 these pathways could take place in this subpopulation.

#### 435 **Putative role of ECM secretion and remodelling by activated EOM MuSCs**

436 Self-renewal in the muscle lineage is dependent on cell-autonomous expression, deposition, and  
437 remodelling of ECM components such as Fibronectin (Bentzinger et al., 2013; Lukjanenko et al., 2016;  
438 Tierney et al., 2016), Col VI (Urciuolo et al., 2013) and Laminin- $\alpha$ 1 (Rayagiri et al., 2018). EOM  
439 progenitors relate more to fetal MuSCs with respect to enrichment in matrisome components such as  
440 Fn1, Fbn1, Vcam and collagens (Tierney et al., 2016). Notably, an extensive and more complex ECM  
441 is observed in EOMs *in vivo* (McLoon et al., 2018). Therefore, we hypothesize that *in vitro* activated  
442 EOM MuSCs secrete high amounts of ECM and self-autonomously maintain stemness when removed  
443 from their niche. For instance, FAPs exert a supportive role in myogenesis by secreted matrix and  
444 cytokine components (Joe et al., 2010; Kotsaris et al., 2023; Murphy et al., 2011; Uezumi et al., 2014).  
445 Myogenic cells expressing mesenchymal markers were also reported in human embryos and from  
446 human iPSCs *in vitro* (Xi et al., 2020). In the EOM, this plasticity was observed *in vivo*, where EOM  
447 myogenic progenitors transition towards non-myogenic cell fates (Grimaldi et al., 2022). Here, we have  
448 extended these observations to the early postnatal period, where considerable proliferation and fusion  
449 occurs. We did so by using using *Pdgfra*<sup>H2BGFP</sup>; *Myf5*<sup>nlacZ</sup> mice and the identification of a subpopulation  
450 of EOM GFP+ cells co-expressing the mesenchymal stem cell marker SCA-1 *in vivo*, which is normally  
451 used as a negative marker of MuSCs (Liu et al., 2015).

#### 452 **A unique network of transcription factors maintains EOM progenitors**

453 Most head regulon genes that we identified in EOM progenitors are not typical myogenic TFs. One of  
454 the most active regulons was *Foxc1*, a pro-mitogenic factor in cancer (Yang et al., 2017) and driver of  
455 endothelial/smooth muscle fates (Lagha et al., 2009; Mayeuf-Louchart et al., 2016; Whitesell et al.,

456 2019). Another top regulon was *Egr1*, which promotes expression of many ECM-related genes (Gaut et  
457 al., 2016; Milet et al., 2017). Interestingly, *Foxc1* and *Ebf1* are active transcription factors underlying the  
458 transition of myogenic towards non-myogenic cell fates in embryonic EOM (Grimaldi et al., 2022). As  
459 *Foxc1* is expressed in quiescent and activated EOM MuSCs, this gene might reinforce a  
460 progenitor/stem-cell identity throughout the lineage. Interestingly, FOXC1 overexpression in TA MuSCs  
461 resulted in upregulation of *Egr1* and downregulation of *Ebf1* in support our bioinformatic analysis  
462 indicating that these TFs form a co-regulatory module.

463 As predicted by our analysis *in silico*, FOXC1 overexpression in TA MuSCs upregulated several EOM  
464 matrisome components and downregulated *Myod*, in accordance with a previous study (Wright et al.,  
465 2021), thereby promoting a less committed state. Given that *Pitx2* appears as a target of *Foxc1* in our  
466 studies (Suppl Table 7) and its overexpression promotes MuSC proliferation and enhances the  
467 regenerative potential of dystrophic MuSCs (Vallejo et al., 2018), we expected an increase in the nuclear  
468 output when overexpressed in TA MuSCs. Yet, we observed the opposite phenotype in pure TA GOF  
469 cultures, thereby raising several possibilities. First, it was reported that sustained expression of FOXC1  
470 can induce stem cell quiescence in the skin (Lay et al., 2016; Wang et al., 2016). Alternatively, a strong  
471 upregulation of FOXC1 might have induced an irreversible drift towards a mesenchymal phenotype in  
472 hindlimb MuSCs as denoted by the reduced expression of *Pax7*. Yet, our mixed GOF cultures also  
473 suggest that the FOXC1-dependent secretome can promote proliferation of adjacent non-transduced  
474 cells. Finally, as *Foxc1* is part of a co-regulatory module in the EOM its singular overexpression might  
475 not be sufficient to confer the full EOM phenotype to limb cells. Future studies should assess the role of  
476 this TF in EOM progenitor emergence and disease.

## 477 **Conclusion**

478 Using in-depth bioinformatic analysis, *in vitro* approaches, and analysis of expression patterns *in vivo*,  
479 we propose a model where the outperformance of EOM MuSCs depends on the expression of a tightly  
480 associated module of transcription factors regulating a distinct pattern of ECM-remodelling factors, cell  
481 receptors and growth factor binding proteins. These components define the pace at which EOM MuSCs  
482 progress through the myogenic lineage and maintenance of a stem-like population. As such, our study  
483 lays the groundwork for elucidating the mechanisms of selective sparing of muscle groups in dystrophic  
484 disease by providing information on a unique core GRN within this muscle group.

## 485 **Materials and methods**

486

### 487 **Animal care**

488 Animals were handled according to national and European Community guidelines and an ethics  
489 committee of the Institut Pasteur (CETEA) in France approved protocols. Except when indicated  
490 otherwise, males and females of 2-4 months were used. *Tg:Pax7-nGFP* (Sambasivan et al., 2009),  
491 *Myf5<sup>Cre</sup>* (Halder et al., 2007), *Myf5<sup>nlacZ</sup>* (Tajbakhsh et al., 1996) *Myog<sup>ntdTom</sup>* (Benavente-Diaz et al., 2021),



492 *Pdgfra*<sup>H2BGFP</sup> (Hamilton et al., 2003), *Pax7*<sup>CreERT2</sup> (Mathew et al., 2011) and *R26*<sup>tdTom</sup> (Madisen et al.,  
493 2009) mouse lines were maintained in a C57Bl/6Jrj background. To induce recombination of  
494 *Pax7*<sup>CreERT2</sup>;*R26*<sup>tdTom</sup> mice a 20 mg/ml stock solution of Tamoxifen was prepared in 5% ethanol and 95%  
495 sunflower seed oil by thorough resuspension with rocking at 4 °C. For adult mice, 2 mg of tamoxifen  
496 (Sigma #T5648) were administered by gavage during 5 consecutive days and animals sacrificed 5 days  
497 later. To induce recombination of pups, the Tamoxifen stock solution was diluted to 15mg/ml with  
498 sunflower seed oil and 0.15 mg were administered daily by subcutaneous injection between P4 and P6  
499 daily. Pups were sacrificed at P10 by decapitation and adult mice by cervical dislocation.

500

#### 501 **Muscle stem cell culture, treatment and transfection**

502 MuSC isolation was performed as described (Gayraud-Morel et al., 2017) with some modifications  
503 indicated in Supplemental Methods. Cells isolated by FACS were cytopun (3 min at 50g at RT) and  
504 plated onto Matrigel® (Corning, 354248) coated dishes and cultured in growth media at 3% O<sub>2</sub>, 5%  
505 CO<sub>2</sub>, 37°C for the indicated time. Half volume of media was changed every second or third day. To  
506 assess proliferation, cells were pulsed with 10<sup>-6</sup> M of EdU (ThermoFisher, C10640) in cell culture media  
507 for 2h prior to fixation. To induce myogenic differentiation and fusion, myoblasts were plated at high  
508 density (33,000 in Figure 7M, Suppl Figure 7R, Z or 75,000 cells/cm<sup>2</sup> in Suppl Figure 1H) onto Matrigel-  
509 coated plates in the growth medium. Once adherent, cells were changed to differentiation medium  
510 (DMEM with 5% serum and 1% P/S).

511 Conditioned media (CM) experiment were performed isolating EOM and TA MuSCs by FACS based on  
512 GFP fluorescence from *Tg:Pax7-nGFP* mice, and collecting the media 3 days post plating. Hindlimb  
513 MuSCs were cultured in growth media (control) or treated with CM from day 1 to day 4 post plating  
514 before analysis.

515 For loss of function experiments, freshly isolated satellite cells from *Tg:Pax7-nGFP* mice were  
516 transfected in suspension immediately after FACS with the ON-TARGET plus SMARTpool against  
517 FOXC1 (Dharmacon, L-047399-01-0005) or Scramble (Dharmacon, ON-TARGETplus Non-targeting  
518 Control siRNA, D0018100205) at 200 nM final concentration using Lipofectamine 3000 (ThermoFisher,  
519 L3000001) in Opti-MEM (Fisher Scientific, 11564506) as described by the manufacturer. Briefly, a pre-  
520 mix of siRNA/Optimem (1.5ul /20ul) and Lipofectamine3000/Optimem (0.3ul / 20ul) were incubated  
521 separately 5 min RT, mixed at 1:1 ratio and incubated 15 min more at RT. 2.10<sup>4</sup> cells in 40ul of Optimem  
522 were incubated with an equal volume of the transfection mix for 2h at 3% O<sub>2</sub>, 5% CO<sub>2</sub>, 37°C in  
523 Eppendorf tubes whose caps had had been punctured with a needle to allow gas exchange. Two hours  
524 after transfection, three volumes of fresh growth medium were added and cells were plated at 10k/cm<sup>2</sup>  
525 in Matrigel coated wells containing growth media. Two days upon transfection wells were processed for  
526 immunostaining or RNA collected with Tryzol as above. Details on immunostaining, RT-qPCR and  
527 Western Blot are described in Supplemental Methods.

528

#### 529 **Lentivirus transduction for gain and loss of function experiments**

530 For GOF assays, in-lab made lentiviral viruses (control (PLVX-CAG-P2A-mCherry) and Foxc1-mCherry  
531 (PLVX-CAG-Foxc1-P2A-mCherry), CAG promoter) and viruses produced by VectorBuilder

532 (<https://en.vectorbuilder.com/>) (control (pLVX-EF1A>mCherry), Foxc1-mCherry (pLVX-EF1A>mFoxc1-  
533 T2A-mCherry), Creb3l1-mCherry (pLVX-EF1A>mCreb3l1-T2A-mCherry), EF1a promoter) were used.  
534 T2A or P2A causes co-translational cleavage of the encoded polypeptide (Supplementary Table 12).  
535 GOF assays of FOXC1 with in-lab or vector builder made viruses were used interchangeably as they  
536 gave comparable results. For LOF assays, three different Foxc1-shRNA vectors were tested with  
537 identical results (U6 promoter for shRNA and hPGK for mCherry reporter).

538  
539 Freshly isolated satellite cells from *Tg:Pax7-nGFP* mice were plated in matrigel coated wells, cultured  
540 overnight and transduced at an MOI (multiplicity of infection) of 100 in 45 $\mu$ l (for 96 well plates) or 125 $\mu$ l  
541 (for 48 well plates) of MuSC media containing 5  $\mu$ g/ml of polybrene. After 4h incubation at 37°C, cells  
542 were washed three times with media and cultured for 4 more days in GM prior to fixation for  
543 immunostaining, protein or RNA collection, or re-sorting of mCherry+ when needed.

544

#### 545 **Image analysis**

546 For cells grown on 96 wells, images from the Opera Phenix high-content microscope were quantified  
547 using Harmony software and a semi-automated pipeline. Nuclei were detected based on Hoechst signal  
548 and mean intensity of fluorescence were automatically quantified on the nuclear region for nuclear  
549 markers. Number of nuclei positive for a certain nuclear marker were scored on a manually defined  
550 threshold. For cells grown on IBIDI 8 well plates, czi images were manually quantified in a blinded  
551 manner using the point toll counter in Fiji (Schindelin et al., 2012) or using the TrackMate7 pipeline  
552 (Ershov et al., 2022).

553 Immunostaining on ECM markers on cells were scanned using either the Opera Phoenix high-content  
554 microscope (Perkin Elmer) or Zeiss LSM800 microscope with ZEN software. Imaging of tissue sections  
555 was done on a Zeiss LSM800 microscope or a Ti2E Spinning disk (Nikon).

556 The fusion index was calculated as the fraction of nuclei contained within MF20+ myotubes, which had  
557 two or more nuclei, as compared to the number of total nuclei within each image.

558 Figures were assembled in Adobe Photoshop, Illustrator and InDesign (Adobe Systems).

559

#### 560 **Time lapse microscopy**

561 MuSC were plated on a microscopy culture chamber (IBIDI, 80826) or 96 wells of TC-Treated Black  
562  $\mu$ CLEAR plates (Greiner Bio-One 655090) and cultured in growth media. The plate was incubated at  
563 37°C, 5% CO<sub>2</sub>, and 3% O<sub>2</sub> (Zeiss, Pecon). A Zeiss Observer.Z1 connected to a Plan-Apochromat  
564 20x/0.8 M27 objective and Hamamatsu Orca Flash 4 camera piloted with Zen (Zeiss) was used. After  
565 activation for 3 days *in vitro*, EOM and TA cells were imaged every 12 min for ~48h. Individual cells  
566 were tracked and tdTOM intensity was scored at selected time points. Tracking of *Myog*<sup>tdTom</sup> cells was  
567 performed using the Manual Tracking feature of the TrackMate plug-in (Tinevez et al., 2017) in Fiji.

568 For lentivirus live imaging experiments, detection of total cell numbers and mCherry positive cells was  
569 done with a custom-made pipeline. To detect cell contours from the bright field images, we retrained the  
570 « livecell » model of CellPose with CellPose 2.0 (Pachitariu and Stringer, 2022). The retraining dataset  
571 was created from small crops of the full data with low density and high density regions and the different

572 cell phenotypes. To homogenize the data, preprocessing of the bright field channel was applied to all the  
573 data: we enhanced the contrast locally with CLAHE (Contrast Limited Adaptive Histogram Equalization)  
574 in Fiji (with a blocksize of 127, default parameters) and normalized the intensity (for each frame). To  
575 assess which cells were infected by the virus (mCherry+), we measured the mean mCherry fluorescent  
576 intensity in each cell normalised by the local mean fluorescent intensity in the well (by averaging the  
577 fluorescent intensity with a radius around 300  $\mu$ m). This allowed to compensate for differences in  
578 illumination even within the same acquisition but can slightly under-estimate the relative intensity of cells  
579 in very dense region. Finally, the mCherry intensity channel was thresholded after a background removal  
580 with Fiji Triangle threshold method calculated with the histogram of the 4 time frames together.  
581 The retrained models were then runned on the full data (cropped regions or full wells) to detect the cell  
582 contours through the Fiji plugin Trackmate-CellPose (Ershov et al., 2022) which allowed us to directly  
583 access measurements of the cells (« spots » table in TrackMate).

584

### 585 **Data analysis and statistics**

586 Data analysis, statistics and visualisations were performed using Prism (Graphpad Software) or using  
587 R (Team, 2014) and the package ggplot2 (Wickham, 2009). Tests are described on Figure legends.  
588 Information related to microarray data analysis and sc-RNAseq of DMD rat EOM are described in  
589 Supplemental Methods.

590

### 591 **scRNAseq data generation**

592 MuSCs were isolated on BD FACSAria™ III based on GFP fluorescence and cell viability from *Tg:Pax7-*  
593 *nGFP mice* (Sambasivan et al., 2009). Quiescent MuSCs were manually counted using a  
594 hemocytometer and immediately processed for scRNA-seq. For activated samples, MuSCs were  
595 cultured *in vitro* as described above for four days. Activated MuSCs were subsequently trypsinized and  
596 washed in DMEM/F12 2% FBS. Live cells were re-sorted, manually counted using a hemocytometer  
597 and processed for scRNA-seq.

598 Prior to scRNAseq, RNA integrity was assessed using Agilent Bioanalyzer 2100 to validate the isolation  
599 protocol (RIN>8 was considered acceptable). 10X Genomics Chromium microfluidic chips were loaded  
600 with around 9000 and cDNA libraries were generated following manufacturer's protocol. Concentrations  
601 and fragment sizes were determined using Agilent Bioanalyzer and Invitrogen Qubit. cDNA libraries  
602 were sequenced using NextSeq 500 and High Output v2.5 (75 cycles) kits. Count matrices were  
603 subsequently generated following 10X Genomics Cell Ranger pipeline.

604 Following normalisation and quality control, we obtained an average of  $5792 \pm 1415$  cells/condition.

605

### 606 **Seurat preprocessing**

607 scRNAseq datasets were processed using Seurat (<https://satijalab.org/seurat/>) (Butler et al., 2018).  
608 Cells with more than 10% of mitochondrial gene fraction were discarded. 4000-5000 genes were  
609 detected on average across all 4 datasets. Dimensionality reduction and UMAPs were generated  
610 following Seurat workflow. The top 100 DEGs were determined using Seurat "FindAllMarkers" function  
611 with default parameters. When processed independently (scvelo), the datasets were first regressed on

612 cell cycle genes, mitochondrial fraction, number of genes, number of UMI following Seurat dedicated  
613 vignette, and doublets were removed using DoubletFinder v3 (McGinnis et al., 2019). A "StressIndex"  
614 score was generated for each cell based on the list of stress genes previously reported (Machado et al.,  
615 2021) using the "AddModule" Seurat function. 94 out of 98 genes were detected in the combined  
616 datasets. UMAPs were generated after 1. StressIndex regression, and 2. after complete removal of the  
617 detected stress genes from the gene expression matrix before normalization. In both cases, the overall  
618 aspect of the UMAP did not change significantly (**Figure S5**). Although immeasurable confounding  
619 effects of cell stress following isolation cannot be ruled out, we reasoned that our datasets did not show  
620 a significant effect of stress with respect to the conclusions of our study.

621

### 622 **Matrisome analysis**

623 After subsetting for the features of the Matrisome database (Naba et al., 2015) present in our single-cell  
624 dataset, the matrisome score was calculated by assessing the overall expression of its constituents  
625 using the "AddModuleScore" function from Seurat (Butler et al., 2018).

626

### 627 **RNA velocity and driver genes**

628 Scvelo was used to calculate RNA velocities (Bergen et al., 2020). Unspliced and spliced transcript  
629 matrices were generated using velocity (Manno et al., 2018) command line function. Seurat-generated  
630 filtering, annotations and cell-embeddings (UMAP, tSNE, PCA) were then added to the outputted  
631 objects. These datasets were then processed following scvelo online guide and documentation. Velocity  
632 was calculated based on the dynamical model (using *scv.tl.recover\_dynamics(adata)*, and  
633 *scv.tl.velocity(adata, mode='dynamical')*) and differential kinetics calculations were added to the model  
634 (using *scv.tl.velocity(adata, diff\_kinetics=True)*). Specific driver genes were identified by determining the  
635 top likelihood genes in the selected cluster. The lists of top 100 drivers for EOM and TA progenitors are  
636 given in Supplemental Tables 10 and 11.

637

### 638 **Gene regulatory network inference and transcription factor modules**

639 Gene regulatory networks were inferred using pySCENIC (Aibar et al., 2017; Sande et al., 2020). This  
640 algorithm regroups sets of correlated genes into regulons (i.e. a transcription factor and its targets)  
641 based on binding motifs and co-expression patterns. The top 35 regulons for each cluster was  
642 determined using scanpy "scanpy.tl.rank\_genes\_groups" function (method=t-test). Note that this  
643 function can yield less than 35 results depending on the cluster. UMAP and heatmap were generated  
644 using regulon AUC matrix (Area Under Curve) which refers to the activity level of each regulon in a given  
645 cell. Visualizations were performed using scanpy (Wolf et al., 2018). The outputted list of each regulon  
646 and their targets was subsequently used to create a transcription factor network. To do so, only genes  
647 that are regulons themselves were kept. This results in a visual representation where each node is an  
648 active transcription factor and each edge is an inferred regulation between 2 transcription factors. When  
649 placed in a force-directed environment, these nodes aggregate based on the number of shared edges.  
650 This operation greatly reduced the number of genes involved, while highlighting co-regulating  
651 transcriptional modules. Visualization of this network was performed in a force-directed graph using

652 Gephi “Force-Atlas2” algorithm (<https://gephi.org/>). Of note, a force-directed graph is a type of  
653 visualization technique where nodes are positioned based on the principles of physics that assign forces  
654 among the set of edges and the set of nodes. Spring like attractive forces are used to attract pairs of  
655 edges towards each other (connected nodes) while repulsive forces, like those of electrically charged  
656 particles, are used to separate all pairs of nodes. In the equilibrium state for this system, the edges tend  
657 to have uniform length (because of the spring forces), and nodes that are not connected by an edge  
658 tend to be drawn further apart (because of the electrical repulsion).

659

### 660 **Gene ontology analysis**

661 Gene ontology analyses were performed on top 100 markers (obtained from Seurat function  
662 FindAllMarkers) or on top 100 driver genes (obtained from scvelo), using Cluego (Bindea et al., 2009).  
663 “GO Molecular Pathway”, and “REACTOME pathways” were used independently to identify common  
664 and unique pathways involved in each dataset. In all analyses, an enrichment/depletion two-sided  
665 hypergeometric test was performed and p-values were corrected using the Bonferroni step down  
666 method. Only the pathways with a p-value lower than 0.05 were displayed.

667

### 668 **Literature scores**

669 The scores for SMMCs (Giordani et al., 2019), FAPs (Oprescu et al., 2020), myotendinous junction B  
670 myonuclei (Kim et al., 2020), Twist2+ population(Liu et al., 2017), fetal MuSCs (Tierney et al., 2016),  
671 developing limb connective tissues (Lima et al., 2021) and the human skeletal muscle mesenchyme (Xi  
672 et al., 2020) were calculated by assessing the overall expression of the markers of each population  
673 (Supplemental Table 5) using the "AddModuleScore" function from Seurat (Butler et al., 2018).

674

### 675 **Code availability and Data availability**

676 The code that was used to generate the TF network is available at this address:  
677 <https://github.com/TajbakhshLab/TFnetwork>. scRNAseq datasets are available in open access on  
678 DRYAD at the following address: (to be updated if manuscript accepted). Raw data scRNAseq  
679 sequencing data have been deposited in the NCBI Gene Expression Omnibus database with the  
680 accession code: GSE244964.

681

### 682 **Acknowledgements**

683 We acknowledge funding support from the Institut Pasteur, Agence Nationale de la Recherche  
684 (Laboratoire d'Excellence Revive, Investissement d'Avenir; ANR-10-LABX-73 to ST and ANR-21-CE13-  
685 0005 MUSE to GC), Association Française contre les Myopathies (Grant #20510 to ST and #23201 to  
686 GC), and the Centre National de la Recherche Scientifique. M.B.D. was supported by a grant from  
687 Laboratoire d'Excellence Revive and La Ligue Contre le Cancer. We gratefully acknowledge the  
688 Genomic Platform (Inserm U1016-CNRS UMRS 8104 - Université de Paris Cité) at Institut Cochin, the  
689 UtechS Photonic Biolmaging (Imagopole), C2RT, Institut Pasteur, supported by the French National  
690 Research Agency (France Biolmaging; ANR-10-INSB-04; Investments for the Future) and the Center  
691 for Translational Science (CRT)-Cytometry and Biomarkers Unit of Technology and Service (CB

692 UTechS) at Institut Pasteur for support in conducting this study. We warmly thank Pierre Henri Comere  
693 for assistance with cell sorting and Marion Louveaux for establishment of the initial image analysis  
694 pipeline.

695

696 **Author contributions**

697 MBD, GC, and ST conceived the study. DDG, MM, MDB, PTL and GC performed experiments. PTL,  
698 SG, MK and BE contributed to *in vitro* experiments and image acquisition. AG, MBD and DDG performed  
699 sc-RNAseq. AG and MBD run the bioinformatic analysis with help from SM and VL. JYT and GL  
700 performed image analysis. AG, MBD and GC wrote the manuscript with input from DDG, MM and ST.  
701 GC and ST provided funding.

702

703

704

705 **REFERENCES**

706  
707

708 **Ahmad, S., Jan, A. T., Baig, M. H., Lee, E. J. and Choi, I.** (2017). Matrix gla protein: An extracellular matrix  
709 protein regulates myostatin expression in the muscle developmental program. *Life Sci* **172**, 55–63.

710 **Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A. A., Imrichova, H., Hulselmans, G.,**  
711 **Rambow, F., Marine, J.-C. C., Geurts, P., Aerts, J., et al.** (2017). SCENIC: single-cell regulatory network  
712 inference and clustering. *Nature methods* **14**, 1083–1086.

713 **Alexakis, C., Partridge, T. and Bou-Gharios, G.** (2007). Implication of the satellite cell in dystrophic muscle  
714 fibrosis: a self-perpetuating mechanism of collagen overproduction. *Am J Physiol-cell Ph* **293**, C661–C669.

715 **Almada, A. E., Horwitz, N., Price, F. D., Gonzalez, A. E., Ko, M., Bolukbasi, O. V., Messemer, K. A.,**  
716 **Chen, S., Sinha, M., Rubin, L. L., et al.** (2021). FOS licenses early events in stem cell activation driving  
717 skeletal muscle regeneration. *Cell Reports* **34**, 108656.

718 **Andrés, V. and Walsh, K.** (1996). Myogenin expression, cell cycle withdrawal, and phenotypic differentiation  
719 are temporally separable events that precede cell fusion upon myogenesis. *J Cell Biology* **132**, 657–66.

720 **Artico, L. L., Laranjeira, Angelo Brunelli Albertoni, Campos, Livia Weijenborg, Correa, J. R., Zenatti, P.**  
721 **P., Carvalheira, J. B. C., Brambilla, S. R., Nowill, A. E., Brandalise, S. R. and Junes, J. A.** (2021).  
722 Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. *Blood advances* **18**.

723 **Baghdadi, M. B., Castel, D., Machado, L., Fukada, S., Birk, D. E., Relaix, F., Tajbakhsh, S. and Mourikis,**  
724 **P.** (2018). Reciprocal signalling by Notch–Collagen V–CALCR retains muscle stem cells in their niche.  
725 *Nature* **557**, 714–718.

726 **Barruet, E., Garcia, S. M., Striedinger, K., Wu, J., Lee, S., Byrnes, L., Wong, A., Xuefeng, S., Tamaki, S.,**  
727 **Brack, A. S., et al.** (2020). Functionally heterogeneous human satellite cells identified by single cell RNA  
728 sequencing. *Elife* **9**, e51576.

729 **Benavente-Diaz, M., Comai, G., Girolamo, D. D., Langa, F. and Tajbakhsh, S.** (2021). Dynamics of  
730 myogenic differentiation using a novel Myogenin knock-in reporter mouse. *Skelet Muscle* **11**, 5.

731 **Bentzinger, F. C., Wang, Y., von Maltzahn, J., Soleimani, V. D., Yin, H. and Rudnicki, M. A.** (2013).  
732 Fibronectin Regulates Wnt7a Signaling and Satellite Cell Expansion. *Cell Stem Cell* **12**, 75–87.

733 **Bergen, V., Lange, M., Peidli, S., Wolf, F. A. and Theis, F. J.** (2020). Generalizing RNA velocity to transient  
734 cell states through dynamical modeling. *Nat Biotechnol* 1–7.

735 **Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès,**  
736 **F., Trajanoski, Z. and Galon, J.** (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped  
737 gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091–1093.

738 **Briggs, D. and Morgan, J. E.** (2013). Recent progress in satellite cell/myoblast engraftment – relevance for  
739 therapy. *FEBS Journal* **280**, 4281–4293.

740 **Brink, S. C. van den, Sage, F., Vértesy, Á., Spanjaard, B., Peterson-Maduro, J., Baron, C. S., Robin, C.**  
741 **and Oudenaarden, A. van** (2017). Single-cell sequencing reveals dissociation-induced gene expression in  
742 tissue subpopulations. *Nat Methods* **14**, 935–936.

743 **Brohmann, H., Jagla, K. and Birchmeier, C.** (2000). The role of Lbx1 in migration of muscle precursor cells.  
744 *Development* **127**, 437–445.

- 745 **Butler, A., Hoffman, P., Smibert, P., Papalexi, E. and Satija, R.** (2018). Integrating single-cell transcriptomic  
746 data across different conditions, technologies, and species. *Nat Biotechnol* **36**, 411–420.
- 747 **Cappellari, O., Benedetti, S., Innocenzi, A., Tedesco, F. S., Moreno-Fortuny, A., Ugarte, G., Lampugnani,  
748 M. G., Messina, G. and Cossu, G.** (2013). Dll4 and PDGF-BB Convert Committed Skeletal Myoblasts to  
749 Pericytes without Erasing Their Myogenic Memory. *Dev Cell* **24**, 586–599.
- 750 **Chakkalakal, J. V., Christensen, J., Xiang, W., Tierney, M. T., Boscolo, F. S., Sacco, A. and Brack, A. S.**  
751 (2014). Early forming label-retaining muscle stem cells require p27kip1 for maintenance of the primitive  
752 state. *Development* **141**, 1649–1659.
- 753 **Charville, G. W., Cheung, T. H., Yoo, B., Santos, P. J., Lee, G. K., Shrager, J. B. and Rando, T. A.** (2015).  
754 Ex Vivo Expansion and In Vivo Self-Renewal of Human Muscle Stem Cells. *Stem Cell Reports* **5**, 621–632.
- 755 **Chen, Z., Li, L., Wu, W., Liu, Z., Huang, Y., Yang, L., Luo, Q., Chen, J., Hou, Y. and Song, G.** (2020).  
756 Exercise protects proliferative muscle satellite cells against exhaustion via the Igfbp7-Akt-mTOR axis.  
757 *Theranostics* **10**, 6448–6466.
- 758 **Cho, W. J., Kim, E. J., Lee, S. J., Kim, H. D., Shin, H. J. and Lim, W. K.** (2000). Involvement of SPARC in  
759 in Vitro Differentiation of Skeletal Myoblasts. *Biochem Bioph Res Co* **271**, 630–634.
- 760 **Clemmons, D. R.** (1997). Insulin-like growth factor binding proteins and their role in controlling IGF actions.  
761 *Cytokine Growth Factor Rev.* **8**, 45–62.
- 762 **Contreras, O., Córdova-Casanova, A. and Brandan, E.** (2021). PDGF-PDGFR network differentially  
763 regulates the fate, migration, proliferation, and cell cycle progression of myogenic cells. *Cell Signal* **84**,  
764 110036.
- 765 **Dell’Orso, S., Juan, A. H., Ko, K.-D., Naz, F., Perovanovic, J., Gutierrez-Cruz, G., Feng, X. and Sartorelli,  
766 V.** (2019). Single cell analysis of adult mouse skeletal muscle stem cells in homeostatic and regenerative  
767 conditions. *Development* **146**, dev174177.
- 768 **Diehl, A. G., Zarepari, S., Qian, M., Khanna, R., Angeles, R. and Gage, P. J.** (2006). Extraocular Muscle  
769 Morphogenesis and Gene Expression Are Regulated by Pitx2 Gene Dose. *Investigative Ophthalmology &  
770 Visual Science* **47**, 1785–1793.
- 771 **Dionyssiou, M. G., Salma, J., Bevzyuk, M., Wales, S., Zakharyan, L. and McDermott, J. C.** (2013).  
772 Krüppel-like factor 6 (KLF6) promotes cell proliferation in skeletal myoblasts in response to TGFβ/Smad3  
773 signaling. *Skelet Muscle* **3**, 7.
- 774 **Dulauroy, S., Carlo, S. E., Langa, F., Eberl, G. and Peduto, L.** (2012). Lineage tracing and genetic ablation  
775 of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury. *Nature  
776 Medicine* **18**, 1262–1270.
- 777 **Dumont, N. A., Wang, Y. X., Maltzahn, J. von, Pasut, A., Bentzinger, C. F., Brun, C. E. and Rudnicki, M.  
778 A.** (2015). Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. *Nat  
779 Med* **21**, 1455–1463.
- 780 **El-Magd, M. A., Abdelfattah-Hassan, A., Elsisy, R. A., Hawsawi, Y. M., Oyouni, A. A., Al-Amer, O. M.  
781 and El-Shetry, E. S.** (2021). Expression and function of Ebfl gene during chondrogenesis in chick embryo  
782 limb buds. *Gene* **803**, 145895.
- 783 **Emery, A. E.** (2002). The muscular dystrophies. *Lancet* **359**, 687–695.
- 784 **Engert, J. C., Berglund, E. B. and Rosenthal, N.** (1996). Proliferation precedes differentiation in IGF-I-  
785 stimulated myogenesis. *J. cell Biol.* **135**, 431–440.



- 786 Ershov, D., Phan, M.-S., Pylvänäinen, J. W., Rigaud, S. U., Blanc, L. L., Charles-Orszag, A., Conway, J.  
787 R. W., Laine, R. F., Roy, N. H., Bonazzi, D., et al. (2022). TrackMate 7: integrating state-of-the-art  
788 segmentation algorithms into tracking pipelines. *Nat. Methods* **19**, 829–832.
- 789 Evano, B. and Tajbakhsh, S. (2018). Skeletal muscle stem cells in comfort and stress. *npj Regenerative*  
790 *Medicine* **3**, 24.
- 791 Evano, B., Gill, D., Hernando-Herraez, I., Comai, G., Stubbs, T. M., Commere, P.-H., Reik, W. and  
792 Tajbakhsh, S. (2020). Transcriptome and epigenome diversity and plasticity of muscle stem cells following  
793 transplantation. *Plos Genet* **16**, e1009022.
- 794 Faggi, F., Chiarelli, N., Colombi, M., Mitola, S., Ronca, R., Madaro, L., Bouche, M., Poliani, P. L., Vezzoli,  
795 M., Longhena, F., et al. (2015). Cavin-1 and Caveolin-1 are both required to support cell proliferation,  
796 migration and anchorage-independent cell growth in rhabdomyosarcoma. *Lab Invest* **95**, 585–602.
- 797 Formicola, L., Marazzi, G. and Sassoon, D. A. (2014). The extraocular muscle stem cell niche is resistant to  
798 ageing and disease. *Front Aging Neurosci* **6**, 328.
- 799 Fukada, S., Uezumi, A., Ikemoto, M., Masuda, S., Segawa, M., Tanimura, N., Yamamoto, H., Miyagoe-  
800 Suzuki, Y. and Takeda, S. (2007). Molecular Signature of Quiescent Satellite Cells in Adult Skeletal  
801 Muscle. *Stem Cells* **25**, 2448–2459.
- 802 Gage, P. J., Suh, H. and Camper, S. A. (1999). Dosage requirement of Pitx2 for development of multiple  
803 organs. *Development* **126**, 4643–4651.
- 804 García, I. A., Demichelis, V. T., Viale, D. L., Giusto, P. D., Ezhova, Y., Polishchuk, R. S., Sampieri, L.,  
805 Martinez, H., Sztul, E. and Alvarez, C. (2017). CREB3L1-mediated functional and structural adaptation of  
806 the secretory pathway in hormone-stimulated thyroid cells. *J Cell Sci* **130**, 4155–4167.
- 807 Gattazzo, F., Laurent, B., Relaix, F., Rouard, H. and Didier, N. (2020a). Distinct Phases of Postnatal Skeletal  
808 Muscle Growth Govern the Progressive Establishment of Muscle Stem Cell Quiescence. *Stem Cell Rep.*
- 809 Gattazzo, F., Laurent, B., Relaix, F., Rouard, H. and Didier, N. (2020b). Distinct Phases of Postnatal Skeletal  
810 Muscle Growth Govern the Progressive Establishment of Muscle Stem Cell Quiescence. *Stem Cell Rep.*
- 811 Gaut, L., Robert, N., Delalande, A., Bonnin, M.-A., Pichon, C. and Duprez, D. (2016). EGR1 Regulates  
812 Transcription Downstream of Mechanical Signals during Tendon Formation and Healing. *Plos One* **11**,  
813 e0166237.
- 814 Gayraud-Morel, B., Chrétien, F., Jory, A., Sambasivan, R., Negroni, E., Flamant, P., Soubigou, G.,  
815 Coppée, J.-Y., Santo, J., Cumanò, A., et al. (2012). Myf5 haploinsufficiency reveals distinct cell fate  
816 potentials for adult skeletal muscle stem cells. *Journal of Cell Science* **125**, 1738–1749.
- 817 Gayraud-Morel, B., Pala, F., Sakai, H. and Tajbakhsh, S. (2017). Isolation of Muscle Stem Cells from  
818 Mouse Skeletal Muscle. *Methods Mol Biology Clifton N J* **1556**, 23–39.
- 819 Gerli, M., Moyle, L., Benedetti, S., Ferrari, G., Ucuncu, E., Ragazzi, M., Constantinou, C., Louca, I.,  
820 Sakai, H., Ala, P., et al. (2019). Combined Notch and PDGF Signaling Enhances Migration and Expression  
821 of Stem Cell Markers while Inducing Perivascular Cell Features in Muscle Satellite Cells. *Stem Cell Rep* **12**,  
822 461–473.
- 823 Giordani, L., He, G. J., Negroni, E., Sakai, H., Law, J., Siu, M. M., Wan, R., Corneau, A., Tajbakhsh, S.,  
824 Cheung, T. H., et al. (2019). High-Dimensional Single-Cell Cartography Reveals Novel Skeletal Muscle-  
825 Resident Cell Populations. *Mol Cell* **74**, 609-621.e6.
- 826 Gnocchi, V. F., White, R. B., Ono, Y., Ellis, J. A. and Zammit, P. S. (2009). Further Characterisation of the  
827 Molecular Signature of Quiescent and Activated Mouse Muscle Satellite Cells. *Plos One* **4**, e5205.

- 828 **Gonçalves, P. R., Nascimento, L. D., Gerlach, R. F., Rodrigues, K. E. and Prado, A. F.** (2022). Matrix  
829 Metalloproteinase 2 as a Pharmacological Target in Heart Failure. *Pharm* **15**, 920.
- 830 **Gopalakrishnan, S., Comai, G., Sambasivan, R., Francou, A., Kelly, R. G. and Tajbakhsh, S.** (2015). A  
831 Cranial Mesoderm Origin for Esophagus Striated Muscles. *Developmental Cell* **34**, 694–704.
- 832 **Grimaldi, A. and Tajbakhsh, S.** (2021). Diversity in cranial muscles: Origins and developmental programs.  
833 *Curr Opin Cell Biol* **73**, 110–116.
- 834 **Grimaldi, A., Comai, G., Mella, S. and Tajbakhsh, S.** (2022). Identification of bipotent progenitors that give  
835 rise to myogenic and connective tissues in mouse. *Elife* **11**, e70235.
- 836 **Gross, M., Moran-Rivard, L., Velasquez, T., Nakatsu, M., Jagla, K. and Goulding, M.** (2000). Lbx1 is  
837 required for muscle precursor migration along a lateral pathway into the limb. *Development (Cambridge,*  
838 *England)* **127**, 413–24.
- 839 **Günther, S., Mielcarek, M., Krüger, M. and Braun, T.** (2004). VITO-1 is an essential cofactor of TEF1-  
840 dependent muscle-specific gene regulation. *Nucleic Acids Res* **32**, 791–802.
- 841 **Guo, K., Wang, J., Andrés, V., Smith, R. C. and Walsh, K.** (1995). MyoD-induced expression of p21 inhibits  
842 cyclin-dependent kinase activity upon myocyte terminal differentiation. *Mol Cell Biol* **15**, 3823–9.
- 843 **Györy, I., Boller, S., Nechanitzky, R., Mandel, E., Pott, S., Liu, E. and Grosschedl, R.** (2012). Transcription  
844 factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. *Gene Dev*  
845 **26**, 668–682.
- 846 **Haldar, M., Hancock, J. D., Coffin, C. M., Lessnick, S. L. and Capecchi, M. R.** (2007). A Conditional  
847 Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin. *Cancer Cell* **11**, 375–388.
- 848 **Hamilton, T. G., Klinghoffer, R. A., Corrin, P. D. and Soriano, P.** (2003). Evolutionary Divergence of  
849 Platelet-Derived Growth Factor Alpha Receptor Signaling Mechanisms. *Mol. Cell. Biol.* **23**, 4013–4025.
- 850 **Han, B., Bhowmick, N., Qu, Y., Chung, S., Giuliano, A. E. and Cui, X.** (2017). FOXC1: an emerging marker  
851 and therapeutic target for cancer. *Oncogene* **36**, 3957–3963.
- 852 **Harel, I., Nathan, E., Tirosh-Finkel, L., Zigdon, H., Guimarães-Camboa, N., Evans, S. M. and Tzahor, E.**  
853 (2009). Distinct Origins and Genetic Programs of Head Muscle Satellite Cells. *Dev Cell* **16**, 822–832.
- 854 **Havis, E. and Duprez, D.** (2020). EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production  
855 in Tendons and Other Connective Tissues. *Int J Mol Sci* **21**, 1664.
- 856 **Hebert, S. L., Daniel, M. L. and McLoon, L. K.** (2013). The Role of Pitx2 in Maintaining the Phenotype of  
857 Myogenic Precursor Cells in the Extraocular Muscles. *PLoS ONE* **8**, e58405.
- 858 **Hellström, M., Kalén, M., Lindahl, P., Abramsson, A. and Betsholtz, C.** (1999). Role of PDGF-B and  
859 PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel  
860 formation in the mouse. *Dev Camb Engl* **126**, 3047–55.
- 861 **Hernando-Herraez, I., Evano, B., Stubbs, T., Commere, P.-H., Bonder, M. J., Clark, S., Andrews, S.,  
862 Tajbakhsh, S. and Reik, W.** (2019). Ageing affects DNA methylation drift and transcriptional cell-to-cell  
863 variability in mouse muscle stem cells. *Nat Commun* **10**, 4361.
- 864 **Honda, M., Hidaka, K., Fukada, S., Sugawa, R., Shirai, M., Ikawa, M. and Morisaki, T.** (2017). Vestigial-  
865 like 2 contributes to normal muscle fiber type distribution in mice. *Sci Rep-uk* **7**, 7168.
- 866 **Ikemoto, M., Fukada, S., Uezumi, A., Masuda, S., Miyoshi, H., Yamamoto, H., Wada, M. R., Masubuchi,  
867 N., Miyagoe-Suzuki, Y. and Takeda, S.** (2007). Autologous Transplantation of SM/C-2.6+ Satellite Cells

- 868 Transduced with Micro-dystrophin CS1 cDNA by Lentiviral Vector into mdx Mice. *Molecular Therapy* **15**,  
869 2178–2185.
- 870 **Ishii, K., Sakurai, H., Suzuki, N., Mabuchi, Y., Sekiya, I., Sekiguchi, K. and Akazawa, C.** (2018).  
871 Recapitulation of Extracellular LAMININ Environment Maintains Stemness of Satellite Cells In Vitro. *Stem*  
872 *Cell Rep* **10**, 568–582.
- 873 **Jen, Y., Weintraub, H. and Benezra, R.** (1992). Overexpression of Id protein inhibits the muscle  
874 differentiation program: in vivo association of Id with E2A proteins. *Gene Dev* **6**, 1466–1479.
- 875 **Jimenez, M. A., Åkerblad, P., Sigvardsson, M. and Rosen, E. D.** (2007). Critical Role for Ebf1 and Ebf2 in  
876 the Adipogenic Transcriptional Cascade. *Mol Cell Biol* **27**, 743–757.
- 877 **Jin, L., Shen, F., Weinfeld, M. and Sergi, C.** (2020). Insulin Growth Factor Binding Protein 7 (IGFBP7)-  
878 Related Cancer and IGFBP3 and IGFBP7 Crosstalk. *Frontiers Oncol* **10**, 727.
- 879 **Jing, Y., Jin, Y., Wang, Y., Chen, S., Zhang, X., Song, Y., Wang, Z., Pu, Y., Ni, Y. and Hu, Q.** (2019).  
880 SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by  
881 PI3K/AKT/PDGFB/PDGFR $\beta$  axis. *J Cell Physiol* **234**, 15581–15593.
- 882 **Joe, A. W. B., Yi, L., Natarajan, A., Grand, F. L., So, L., Wang, J., Rudnicki, M. A. and Rossi, F. M. V.**  
883 (2010). Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nat Cell Biol*  
884 **12**, 153–163.
- 885 **Kallestad, K. M., Hebert, S. L., McDonald, A. A., Daniel, M. L., Cu, S. R. and McLoon, L. K.** (2011).  
886 Sparing of extraocular muscle in aging and muscular dystrophies: A myogenic precursor cell hypothesis.  
887 *Experimental Cell Research* **317**, 873–885.
- 888 **Kelly, R. G., Jerome-Majewska, L. A. and Papaioannou, V. E.** (2004). The del22q11.2 candidate gene Tbx1  
889 regulates branchiomic myogenesis. *Human Molecular Genetics* **13**, 2829–2840.
- 890 **Kida, Y. and Yamaguchi, I.** (2022). The vascular protective effect of matrix Gla protein during kidney injury.  
891 *Frontiers Mol Medicine* **2**, 970744.
- 892 **Kim, M., Franke, V., Brandt, B., Lowenstein, E. D., Schöwel, V., Spuler, S., Akalin, A. and Birchmeier, C.**  
893 (2020). Single-nucleus transcriptomics reveals functional compartmentalization in syncytial skeletal muscle  
894 cells. *Nat Commun* **11**, 6375.
- 895 **Kotsaris, G., Qazi, T. H., Bucher, C. H., Zahid, H., Pöhle-Kronawitter, S., Ugorets, V., Jarassier, W.,**  
896 **Börno, S., Timmermann, B., Giesecke-Thiel, C., et al.** (2023). Odd skipped-related 1 controls the pro-  
897 regenerative response of fibro-adipogenic progenitors. *npj Regen. Med.* **8**, 19.
- 898 **Kühl, U., Öcalan, M., Timpl, R., Mayne, R., Hay, E. and Mark, K. von der** (1984). Role of muscle  
899 fibroblasts in the deposition of type-IV collagen in the basal lamina of myotubes. *Differentiation* **28**, 164–  
900 172.
- 901 **Kumar, D., Shadrach, J. L., Wagers, A. J. and Lassar, A. B.** (2009). Id3 Is a Direct Transcriptional Target of  
902 Pax7 in Quiescent Satellite Cells. *Mol Biol Cell* **20**, 3170–3177.
- 903 **Lagha, M., Brunelli, S., Messina, G., Cumano, A., Kume, T., Relaix, F. and Buckingham, M. E.** (2009).  
904 Pax3:Foxc2 Reciprocal Repression in the Somite Modulates Muscular versus Vascular Cell Fate Choice in  
905 Multipotent Progenitors. *Dev Cell* **17**, 892–899.
- 906 **Laumonier, T., Bermont, F., Hoffmeyer, P., Kindler, V. and Menetrey, J.** (2017). Human myogenic reserve  
907 cells are quiescent stem cells that contribute to muscle regeneration after intramuscular transplantation in  
908 immunodeficient mice. *Sci Rep-uk* **7**, 3462.

- 909 **Lay, K., Kume, T. and Fuchs, E.** (2016). FOXC1 maintains the hair follicle stem cell niche and governs stem  
910 cell quiescence to preserve long-term tissue-regenerating potential. *Proc. Natl. Acad. Sci.* **113**, E1506–  
911 E1515.
- 912 **Levéen, P., Pekny, M., Gebre-Medhin, S., Swolin, B., Larsson, E. and Betsholtz, C.** (1994). Mice deficient  
913 for PDGF B show renal, cardiovascular, and hematological abnormalities. *Gene Dev* **8**, 1875–1887.
- 914 **L'honoré, A., Commère, P.-H., Negroni, E., Pallafacchina, G., Friguet, B., Drouin, J., Buckingham, M.**  
915 **and Montarras, D.** (2018). The role of Pitx2 and Pitx3 in muscle stem cells gives new insights into P38 $\alpha$   
916 MAP kinase and redox regulation of muscle regeneration. *eLife* **7**, e32991.
- 917 **Li, X., Wei, R., Wang, M., Ma, L., Zhang, Z., Chen, L., Guo, Q., Guo, S., Zhu, S., Zhang, S., et al.** (2020).  
918 MGP Promotes Colon Cancer Proliferation by Activating the NF- $\kappa$ B Pathway through Upregulation of the  
919 Calcium Signaling Pathway. *Mol Ther - Oncolytics* **17**, 371–383.
- 920 **Lima, J. E. de, Blavet, C., Bonnin, M.-A., Hirsinger, E., Comai, G., Yvernogeu, L., Delfini, M.-C.,**  
921 **Bellenger, L., Mella, S., Nassari, S., et al.** (2021). Unexpected contribution of fibroblasts to muscle lineage  
922 as a mechanism for limb muscle patterning. *Nat Commun* **12**, 3851.
- 923 **Liu, L., Cheung, T. H., Charville, G. W. and Rando, T. A.** (2015). Isolation of skeletal muscle stem cells by  
924 fluorescence-activated cell sorting. *Nat. Protoc.* **10**, 1612–1624.
- 925 **Liu, N., Garry, G. A., Li, S., Bezprozvannaya, S., Sanchez-Ortiz, E., Chen, B., Shelton, J. M., Jaichander,**  
926 **P., Bassel-Duby, R. and Olson, E. N.** (2017). A Twist2-dependent progenitor cell contributes to adult  
927 skeletal muscle. *Nat Cell Biol* **19**, 202–213.
- 928 **Lukjanenko, L., Jung, J. M., Hegde, N., Perruisseau-Carrier, C., Migliavacca, E., Rozo, M., Karaz, S.,**  
929 **Jacot, G., Schmidt, M., Li, L., et al.** (2016). Loss of fibronectin from the aged stem cell niche affects the  
930 regenerative capacity of skeletal muscle in mice. *Nature Medicine* **22**, 897–905.
- 931 **Machado, L., Lima, J. E. de, Fabre, O., Proux, C., Legendre, R., Szegedi, A., Varet, H., Ingerslev, L. R.,**  
932 **Barrès, R., Relaix, F., et al.** (2017). In Situ Fixation Redefines Quiescence and Early Activation of Skeletal  
933 Muscle Stem Cells. *Cell Reports* **21**, 1982–1993.
- 934 **Machado, L., Geara, P., Camps, J., Santos, M. D., Teixeira-Clerc, F., Herck, J. V., Varet, H., Legendre,**  
935 **R., Pawlotsky, J.-M., Sampaolesi, M., et al.** (2021). Tissue damage induces a conserved stress response  
936 that initiates quiescent muscle stem cell activation. *Cell Stem Cell*.
- 937 **Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D.,**  
938 **Hawrylycz, M. J., Jones, A. R., et al.** (2009). A robust and high-throughput Cre reporting and  
939 characterization system for the whole mouse brain. *Nature Neuroscience* **13**, 133–140.
- 940 **Maeda, T., Chapman, D. L. and Stewart, A. F. R.** (2002). Mammalian Vestigial-like 2, a Cofactor of TEF-1  
941 and MEF2 Transcription Factors That Promotes Skeletal Muscle Differentiation\*. *J Biol Chem* **277**, 48889–  
942 48898.
- 943 **Manno, G. L., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K.,**  
944 **Kastriti, M. E., Lönnerberg, P., Furlan, A., et al.** (2018). RNA velocity of single cells. *Nature* **560**, 494–  
945 498.
- 946 **Mathew, S. J., Hansen, J. M., Merrell, A. J., Murphy, M. M., Lawson, J. A., Hutcheson, D. A., Hansen, M.**  
947 **S., Angus-Hill, M. and Kardon, G.** (2011). Connective tissue fibroblasts and Tcf4 regulate myogenesis.  
948 *Development* **138**, 371–384.
- 949 **Mayeuf-Louchart, A., Montarras, D., Bodin, C., Kume, T., Vincent, S. D. and Buckingham, M.** (2016).  
950 Endothelial cell specification in the somite is compromised in Pax3-positive progenitors of Foxc1/2  
951 conditional mutants, with loss of forelimb myogenesis. *Development* **143**, 872–879.

- 952 **McDavid, A., Finak, G. and Gottardo, R.** (2016). The contribution of cell cycle to heterogeneity in single-cell  
953 RNA-seq data. *Nat Biotechnol* **34**, 591–593.
- 954 **McGinnis, C. S., Murrow, L. M. and Gartner, Z. J.** (2019). DoubletFinder: Doublet Detection in Single-Cell  
955 RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* **8**, 329-337.e4.
- 956 **McLoon, L. K., Vicente, A., Fitzpatrick, K. R., Lindström, M. and Domellöf, F.** (2018). Composition,  
957 Architecture, and Functional Implications of the Connective Tissue Network of the Extraocular Muscles.  
958 *Investigative Ophthalmology & Visual Science* **59**, 322–329.
- 959 **Melouane, A., Carbonell, A., Yoshioka, M., Puymirat, J. and St-Amand, J.** (2018). Implication of SPARC in  
960 the modulation of the extracellular matrix and mitochondrial function in muscle cells. *Plos One* **13**,  
961 e0192714.
- 962 **Michailovici, I., Eigler, T. and Tzahor, E.** (2015). Chapter One Craniofacial Muscle Development. *Curr Top*  
963 *Dev Biol* **115**, 3–30.
- 964 **Micheli, A. J. D., Laurilliard, E. J., Heinke, C. L., Ravichandran, H., Fraczek, P., Soueid-Baumgarten, S.,**  
965 **Vlaminck, I., Elemento, O. and Cosgrove, B. D.** (2020). Single-Cell Analysis of the Muscle Stem Cell  
966 Hierarchy Identifies Heterotypic Communication Signals Involved in Skeletal Muscle Regeneration. *Cell*  
967 *Reports* **30**, 3583-3595.e5.
- 968 **Milet, C., Bléher, M., Allbright, K., Orgeur, M., Couplier, F., Duprez, D. and Havis, E.** (2017). Egr1  
969 deficiency induces browning of inguinal subcutaneous white adipose tissue in mice. *Sci Rep-uk* **7**, 16153.
- 970 **Montarras, D., Morgan, J., Collins, C., Relaix, F., Zaffran, S., Cumano, A., Partridge, T. and**  
971 **Buckingham, M.** (2005). Direct Isolation of Satellite Cells for Skeletal Muscle Regeneration. *Science* **309**,  
972 2064–2067.
- 973 **Moreno, C. S.** (2019). SOX4: The Unappreciated Oncogene. *Semin Cancer Biol* **67**, 57–64.
- 974 **Morree, A. de, Klein, J. D. D., Gan, Q., Farup, J., Urtasun, A., Kanugovi, A., Bilen, B., Velthoven, C. T. J.**  
975 **van, Quarta, M. and Rando, T. A.** (2019). Alternative polyadenylation of Pax3 controls muscle stem cell  
976 fate and muscle function. *Science* **366**, 734–738.
- 977 **Mourikis, P., Sambasivan, R., Castel, D., Rocheteau, P., Bizzarro, V. and Tajbakhsh, S.** (2012). A Critical  
978 Requirement for Notch Signaling in Maintenance of the Quiescent Skeletal Muscle Stem Cell State. *Stem*  
979 *Cells* **30**, 243–252.
- 980 **Mu, X., Urso, M. L., Murray, K., Fu, F. and Li, Y.** (2010). Relaxin Regulates MMP Expression and Promotes  
981 Satellite Cell Mobilization During Muscle Healing in Both Young and Aged Mice. *Am J Pathology* **177**,  
982 2399–2410.
- 983 **Murphy, M. M., Lawson, J. A., Mathew, S. J., Hutcheson, D. A. and Kardon, G.** (2011). Satellite cells,  
984 connective tissue fibroblasts and their interactions are crucial for muscle regeneration. *Development* **138**,  
985 3625–3637.
- 986 **Naba, A., Clauser, K. R., Ding, H., Whittaker, C. A., Carr, S. A. and Hynes, R. O.** (2015). The extracellular  
987 matrix: Tools and insights for the “omics” era. *Matrix Biology J Int Soc Matrix Biology* **49**, 10–24.
- 988 **Noguchi, Y., Nakamura, M., Hino, N., Nogami, J., Tsuji, S., Sato, T., Zhang, L., Tsujikawa, K., Tanaka,**  
989 **T., Izawa, K., et al.** (2019). Cell-autonomous and redundant roles of Hey1 and HeyL in muscle stem cells:  
990 HeyL requires Hes1 to bind diverse DNA sites. *Development* **146**, dev163618.
- 991 **Olguin, H. C. and Olwin, B. B.** (2004). Pax-7 up-regulation inhibits myogenesis and cell cycle progression in  
992 satellite cells: a potential mechanism for self-renewal. *Dev Biol* **275**, 375–388.

- 993 **Ono, Y., Masuda, S., Nam, H., Benezra, R., Miyagoe-Suzuki, Y. and Takeda, S.** (2012). Slow-dividing  
994 satellite cells retain long-term self-renewal ability in adult muscle. *J Cell Sci* **125**, 1309–1317.
- 995 **Oprescu, S. N., Yue, F., Qiu, J., Brito, L. F. and Kuang, S.** (2020). Temporal Dynamics and Heterogeneity of  
996 Cell Populations during Skeletal Muscle Regeneration. *Iscience* **23**, 100993.
- 997 **Pachitariu, M. and Stringer, C.** (2022). Cellpose 2.0: how to train your own model. *Nat. Methods* **19**, 1634–  
998 1641.
- 999 **Pagani, F., Tratta, E., Dell’Era, P., Cominelli, M. and Poliani, P. L.** (2021). EBF1 is expressed in pericytes  
1000 and contributes to pericyte cell commitment. *Histochem Cell Biol* **156**, 333–347.
- 1001 **Randolph, M. E. and Pavlath, G. K.** (2015). A muscle stem cell for every muscle: variability of satellite cell  
1002 biology among different muscle groups. *Frontiers in Aging Neuroscience* **7**, 190.
- 1003 **Rayagiri, S., Ranaldi, D., Raven, A., Azhar, N., Lefebvre, O., Zammit, P. S. and Borycki, A.-G.** (2018).  
1004 Basal lamina remodeling at the skeletal muscle stem cell niche mediates stem cell self-renewal. *Nature*  
1005 *Communications* **9**, 1075.
- 1006 **Relaix, F. and Zammit, P. S.** (2012). Satellite cells are essential for skeletal muscle regeneration: the cell on the  
1007 edge returns centre stage. *Development* **139**, 2845–2856.
- 1008 **Rocheteau, P., Gayraud-Morel, B., Siegl-Cachedenier, I., Blasco, M. A. and Tajbakhsh, S.** (2012). A  
1009 subpopulation of adult skeletal muscle stem cells retains all template DNA strands after cell division. *Cell*  
1010 **148**, 112–25.
- 1011 **Rugowska, A., Starosta, A. and Konieczny, P.** (2021). Epigenetic modifications in muscle regeneration and  
1012 progression of Duchenne muscular dystrophy. *Clin Epigenetics* **13**, 13.
- 1013 **Sakai, H., Sato, T., Sakurai, H., Yamamoto, T., Hanaoka, K., Montarras, D. and Sehara-Fujisawa, A.**  
1014 (2013). Fetal Skeletal Muscle Progenitors Have Regenerative Capacity after Intramuscular Engraftment in  
1015 Dystrophin Deficient Mice. *Plos One* **8**, e63016.
- 1016 **Sambasivan, R., Gayraud-Morel, B., Dumas, G., Cimper, C., Paisant, S., Kelly, R. G. and Tajbakhsh, S.**  
1017 (2009). Distinct Regulatory Cascades Govern Extraocular and Pharyngeal Arch Muscle Progenitor Cell  
1018 Fates. *Developmental Cell* **16**, 810–821.
- 1019 **Sambasivan, R., Kuratani, S. and Tajbakhsh, S.** (2011). An eye on the head: the development and evolution  
1020 of craniofacial muscles. *Development* **138**, 2401–15.
- 1021 **Sampath, S. C., Sampath, S. C. and Millay, D. P.** (2018). Myoblast fusion confusion: the resolution begins.  
1022 *Skeletal Muscle* **8**, 3.
- 1023 **Sampieri, L., Giusto, P. D. and Alvarez, C.** (2019). CREB3 Transcription Factors: ER-Golgi Stress  
1024 Transducers as Hubs for Cellular Homeostasis. *Frontiers Cell Dev Biology* **7**, 123.
- 1025 **Sande, B. V. de, Flerin, C., Davie, K., Waegeneer, M. D., Hulselmans, G., Aibar, S., Seurinck, R., Saelens,  
1026 W., Cannoodt, R., Rouchon, Q., et al.** (2020). A scalable SCENIC workflow for single-cell gene regulatory  
1027 network analysis. *Nat Protoc* 1–30.
- 1028 **Scaramozza, A., Park, D., Kollu, S., Beerman, I., Sun, X., Rossi, D. J., Lin, C. P., Scadden, D. T., Crist, C.  
1029 and Brack, A. S.** (2019). Lineage Tracing Reveals a Subset of Reserve Muscle Stem Cells Capable of  
1030 Clonal Expansion under Stress. *Cell Stem Cell* **24**, 944-957.e5.
- 1031 **Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,  
1032 Rueden, C., Saalfeld, S., Schmid, B., et al.** (2012). Fiji: an open-source platform for biological-image  
1033 analysis. *Nat Methods* **9**, 676–682.

- 1034 **Shao, X. and Wei, X.** (2018). FOXP1 enhances fibrosis via activating Wnt/ $\beta$ -catenin signaling pathway in  
1035 endometriosis. *Am J Transl Res* **10**, 3610–3618.
- 1036 **Smith, R. S., Zabaleta, A., Kume, T., Savinova, O. V., Kidson, S. H., Martin, J. E., Nishimura, D. Y.,**  
1037 **Alward, W. L. M., Hogan, B. L. M. and John, S. W. M.** (2000). Haploinsufficiency of the transcription  
1038 factors FOXC1 and FOXC2 results in aberrant ocular development. *Hum Mol Genet* **9**, 1021–1032.
- 1039 **Soriano, P.** (1994). Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant  
1040 mice. *Gene Dev* **8**, 1888–1896.
- 1041 **Stuelsatz, P., Shearer, A., Li, Y., Muir, L. A., Ieronimakis, N., Shen, Q. W., Kirillova, I. and Yablonka-**  
1042 **Reuveni, Z.** (2015). Extraocular muscle satellite cells are high performance myo-engines retaining efficient  
1043 regenerative capacity in dystrophin deficiency. *Dev Biol* **397**, 31–44.
- 1044 **Swinehart, I. T., Schlientz, A. J., Quintanilla, C. A., Mortlock, D. P. and Wellik, D. M.** (2013). Hox11 genes  
1045 are required for regional patterning and integration of muscle, tendon and bone. *Development* **140**, 4574–  
1046 4582.
- 1047 **Taglietti, V., Kefi, K., Rivera, L., Bergiers, O., Cardone, N., Couplier, F., Gioftsi, S., Drayton-Libotte,**  
1048 **B., Hou, C., Authier, F.-J., et al.** (2023). Thyroid-stimulating hormone receptor signaling restores skeletal  
1049 muscle stem cell regeneration in rats with muscular dystrophy. *Sci Transl Med* **15**, eadd5275.
- 1050 **Tajbakhsh, S., Rocancourt, D. and Buckingham, M.** (1996). Muscle progenitor cells failing to respond to  
1051 positional cues adopt non-myogenic fates in myf-5 null mice. *Nature* **384**, 266–270.
- 1052 **Tajbakhsh, S., Rocancourt, D., Cossu, G. and Buckingham, M.** (1997). Redefining the Genetic Hierarchies  
1053 Controlling Skeletal Myogenesis: Pax-3 and Myf-5 Act Upstream of MyoD. *Cell* **89**, 127–138.
- 1054 **Team, R. C.** (2014). R: A language and environment for statistical computing. R Foundation for Statistical.
- 1055 **Terry, E. E., Zhang, X., Hoffmann, C., Hughes, L. D., Lewis, S. A., Li, J., Wallace, M. J., Riley, L.,**  
1056 **Douglas, C. M., Gutierrez-Montreal, M. A., et al.** (2018). Transcriptional profiling reveals extraordinary  
1057 diversity among skeletal muscle tissues. *eLife* **7**, e34613.
- 1058 **Tierney, M., Gromova, A., Sesillo, F., Sala, D., Spenlé, C., Orend, G. and Sacco, A.** (2016). Autonomous  
1059 Extracellular Matrix Remodeling Controls a Progressive Adaptation in Muscle Stem Cell Regenerative  
1060 Capacity during Development. *Cell Reports* **14**, 1940–1952.
- 1061 **Tierney, M. T., Stec, M. J., Rulands, S., Simons, B. D. and Sacco, A.** (2018). Muscle Stem Cells Exhibit  
1062 Distinct Clonal Dynamics in Response to Tissue Repair and Homeostatic Aging. *Cell Stem Cell* **22**, 119–  
1063 127.e3.
- 1064 **Tinevez, J.-Y., Perry, N., Schindelin, J., Hoopes, G. M., Reynolds, G. D., Laplantine, E., Bednarek, S. Y.,**  
1065 **Shorte, S. L. and Eliceiri, K. W.** (2017). TrackMate: An open and extensible platform for single-particle  
1066 tracking. *Methods* **115**, 80–90.
- 1067 **Uezumi, A., Fukada, S., Yamamoto, N., Takeda, S. and Tsuchida, K.** (2010). Mesenchymal progenitors  
1068 distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. *Nat Cell Biol* **12**, 143–  
1069 152.
- 1070 **Uezumi, A., Ikemoto-Uezumi, M. and Tsuchida, K.** (2014). Roles of nonmyogenic mesenchymal progenitors  
1071 in pathogenesis and regeneration of skeletal muscle. *Front. Physiol.* **5**, 68.
- 1072 **Urciuolo, A., Quarta, M., Morbidoni, V., Gattazzo, F., Molon, S., Grumati, P., Montemurro, F., Tedesco,**  
1073 **F. S., Blaauw, B., Cossu, G., et al.** (2013). Collagen VI regulates satellite cell self-renewal and muscle  
1074 regeneration. *Nat. Commun.* **4**, 1964.

- 1075 **Vallejo, D., Hernández-Torres, F., Lozano-Velasco, E., Rodríguez-Outeiriño, L., Carvajal, A., Creus, C.,**  
1076 **Franco, D. and Aránega, A. E.** (2018). PITX2 Enhances the Regenerative Potential of Dystrophic Skeletal  
1077 Muscle Stem Cells. *Stem Cell Rep* **10**, 1398–1411.
- 1078 **Vartanian, A. D., Quéting, M., Michineau, S., Auradé, F., Hayashi, S., Dubois, C., Rocancourt, D., Drayton-**  
1079 **Libotte, B., Szegedi, A., Buckingham, M., et al.** (2019). PAX3 Confers Functional Heterogeneity in  
1080 Skeletal Muscle Stem Cell Responses to Environmental Stress. *Cell Stem Cell* **24**, 958-973.e9.
- 1081 **Velthoven, C. T. J. van, Morree, A. de, Egner, I. M., Brett, J. O. and Rando, T. A.** (2017). Transcriptional  
1082 Profiling of Quiescent Muscle Stem Cells In Vivo. *Cell Reports* **21**, 1994–2004.
- 1083 **Verma, M., Fitzpatrick, K. R. and McLoon, L. K.** (2017). Extraocular Muscle Repair and Regeneration. *Curr*  
1084 *Ophthalmol Reports* **5**, 207–215.
- 1085 **Vicente-García, C., Hernández-Camacho, J. D. and Carvajal, J. J.** (2022). Regulation of myogenic gene  
1086 expression. *Exp. Cell Res.* **419**, 113299.
- 1087 **Wang, L., Siegenthaler, J. A., Dowell, R. D. and Yi, R.** (2016). Foxc1 reinforces quiescence in self-renewing  
1088 hair follicle stem cells. *Science* **351**, 613–617.
- 1089 **Whitesell, T. R., Chrystal, P. W., Ryu, J.-R., Munsie, N., Grosse, A., French, C. R., Workentine, M. L., Li,**  
1090 **R., Zhu, L. J., Waskiewicz, A., et al.** (2019). foxc1 is required for embryonic head vascular smooth muscle  
1091 differentiation in zebrafish. *Dev Biol* **453**, 34–47.
- 1092 **Wickham, H.** (2009). ggplot2, Elegant Graphics for Data Analysis.
- 1093 **Wolf, F. A., Angerer, P. and Theis, F. J.** (2018). SCANPY: large-scale single-cell gene expression data  
1094 analysis. *Genome Biol* **19**, 15.
- 1095 **Wright, W. E., Li, C., Zheng, C.-X. and Tucker, H. O.** (2021). FOXP1 Interacts with MyoD to Repress its  
1096 Transcription and Myoblast Conversion. *J. Cell. Signal.* **2**, 9–26.
- 1097 **Xi, H., Langerman, J., Sabri, S., Chien, P., Young, C. S., Younesi, S., Hicks, M., Gonzalez, K., Fujiwara,**  
1098 **W., Marzi, J., et al.** (2020). A Human Skeletal Muscle Atlas Identifies the Trajectories of Stem and  
1099 Progenitor Cells across Development and from Human Pluripotent Stem Cells. *Cell Stem Cell* **27**, 158-  
1100 176.e10.
- 1101 **Xie, N., Chu, S. N., Azzag, K., Schultz, C. B., Peifer, L. N., Kyba, M., Perlingeiro, R. C. R. and Chan, S. S.**  
1102 **K.** (2021). In vitro expanded skeletal myogenic progenitors from pluripotent stem cell-derived teratomas  
1103 have high engraftment capacity. *Stem Cell Rep.*
- 1104 **Yang, Z., Jiang, S., Cheng, Y., Li, T., Hu, W., Ma, Z., Chen, F. and Yang, Y.** (2017). FOXC1 in cancer  
1105 development and therapy: deciphering its emerging and divergent roles. *Ther Adv Med Oncol* **9**, 797–816.
- 1106 **Yartseva, V., Goldstein, L. D., Rodman, J., Kates, L., Chen, M. Z., Chen, Y.-J. J., Foreman, O., Siebel, C.**  
1107 **W., Modrusan, Z., Peterson, A. S., et al.** (2020). Heterogeneity of Satellite Cells Implicates  
1108 DELTA1/NOTCH2 Signaling in Self-Renewal. *Cell Reports* **30**, 1491-1503.e6.
- 1109 **Yennek, S., Burute, M., Théry, M. and Tajbakhsh, S.** (2014). Cell Adhesion Geometry Regulates Non-  
1110 Random DNA Segregation and Asymmetric Cell Fates in Mouse Skeletal Muscle Stem Cells. *Cell Reports* **7**,  
1111 961–970.
- 1112 **Yin, H., Price, F. and Rudnicki, M. A.** (2013). Satellite cells and the muscle stem cell niche. *Physiol Rev* **93**,  
1113 23–67.



- 1114 **Yoshida, N., Yoshida, S., Koishi, K., Masuda, K. and Nabeshima, Y.** (1998). Cell heterogeneity upon  
1115 myogenic differentiation: down-regulation of MyoD and Myf-5 generates “reserve cells”. *J Cell Sci* **111** ( Pt  
1116 **6**), 769–79.
- 1117 **Yoshioka, K., Nagahisa, H., Miura, F., Araki, H., Kamei, Y., Kitajima, Y., Seko, D., Nogami, J., Tsuchiya,**  
1118 **Y., Okazaki, N., et al.** (2021). Hoxa10 mediates positional memory to govern stem cell function in adult  
1119 skeletal muscle. *Sci Adv* **7**, eabd7924.
- 1120 **Zacharias, A. L., Lewandoski, M., Rudnicki, M. A. and Gage, P. J.** (2011). Pitx2 is an upstream activator of  
1121 extraocular myogenesis and survival. *Dev Biol* **349**, 395–405.
- 1122 **Zakany, J. and Duboule, D.** (2007). The role of Hox genes during vertebrate limb development. *Curr Opin*  
1123 *Genet Dev* **17**, 359–366.
- 1124 **Zammit, P. S., Golding, J. P., Nagata, Y., Hudon, V., Partridge, T. A. and Beauchamp, J. R.** (2004).  
1125 Muscle satellite cells adopt divergent fates. *The Journal of Cell Biology* **166**, 347–357.
- 1126 **Zhang, P., Wong, C., Liu, D., Finegold, M., Harper, J. W. and Elledge, S. J.** (1999). p21CIP1 and p57KIP2  
1127 control muscle differentiation at the myogenin step. *Gene Dev* **13**, 213–224.
- 1128  
1129

1130 **FIGURE LEGENDS**

1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156

**Figure 1. Functional differences between EOM and TA MuSCs following activation.**

- A. Experimental scheme. Adult MuSCs isolated from *Tg:Pax7-nGFP* mice were plated in growth media (GM) and pulsed with EdU before fixation and immunostaining at Day (D) 3, D4, D5 and D10.
  - B. Immunofluorescence for MF20, PAX7 and EdU detection as per in A. Scale bar 100µm.
  - C-D. Bar plots of total number of nuclei and EdU+ nuclei represented as EOM/TA fold change (C) and percentage of EdU+ cells/total number of nuclei at D3, D4, D5. N>3 independent experiments with n≥3 mice per experiment.
  - E. Quantification of the percentage of Pax7+ cells/total number of nuclei at D10. n≥3 mice.
  - F. Quantification of the Fusion Index at D10. n=4 mice.
  - G. Experimental scheme. Live imaging of adult EOM and TA MuSCs from *Tg:Pax7-nGFP;Myog<sup>ntdTom</sup>* from D3 *in vitro*.
  - H. Representative overlaid DIC and red fluorescence channel images at selected time points. Scale bar 25 µm.
  - I. Percentage of tdTom+ cells over total cell number at each timepoint. n=4 mice.
  - J. RT-qPCR on *in vitro* activated adult EOM and TA MuSCs for *Pax7*, *Myod*, *Myogenin* and *p21* normalized to *Rpl13*. n=8 mice.
  - K. Experimental scheme. Adult MuSCs from *Tg:Pax7-nGFP;Myog<sup>ntdTom</sup>* mice were cultured for 5 days and re-sorted based on GFP and tdTom fluorescence for further analysis.
  - L. RT-qPCR for key myogenic markers of cells isolated as per in K. n=4 mice.
- Data presented as mean ± SEM. Two-tailed unpaired Student's t-test; ns, non-significant, p-value>0.05, \* p-value < 0.05, \*\* p-value<0.01, \*\*\* p-value < 0.005, \*\*\*\* p-value<0.0001. GM, growth media; DM, differentiation media.

1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167

**Figure 2. Single cell transcriptome signatures of activated EOM and TA MuSCs.**

- A. sc-RNAseq pipeline for *in vitro* activated adult MuSCs.
- B. UMAP visualization of EOM progenitors, EOM differentiating, TA progenitors, and TA differentiating clusters (left). Violin plots of the expression of myogenic markers *Pax7* (progenitor), *Myod* (committed) and *Myog* (differentiating) in each cluster (right).
- C. Expression plots of myogenic markers.
- D. Heatmap representing top differentially expressed genes in each cluster and expression levels across all cells.
- E-F. Reactome pathway (E) and GO Molecular function (F) network analysis on top 100 DEGs of each cluster. Pie charts represent relative contribution of each cluster to this ontology term.

1168 **Figure 3. Molecular signature of EOM and TA quiescent MuSCs.**

- A. sc-RNAseq pipeline for quiescent adult MuSCs.
- B. UMAP visualization of EOM and TA quiescent clusters.
- C-D. Violin plot (C) and expression plot (D) of *Myf5*, *Pax7*, *Myod* and *Myog*.
- E. Heatmap representing top differentially expressed genes in each cluster and expression levels across all cells.
- F-G. Venn diagrams of the overlapping differentially expressed genes between quiescent and global *in vitro* activated datasets for EOM (F) and TA (G).
- H-I. Expression plots of selected EOM (H) and TA (I) markers exclusive to Quiescence (Unique Q), common to quiescent and activated states (Conserved) and exclusive to activation (Unique Act) from the analysis in F-G.

1179

**Figure 4. EOM MuSC activation is accompanied by ECM remodelling.**

- A. Violin plots of matrisome scores for each cluster of the *in vitro* activated sc-RNAseq dataset.
- B. Dot plot visualisation of differentially expressed matrisome components. ECM, extracellular matrix; A-P, affiliated proteins; PG, proteoglycans.
- C. Immunofluorescence for Fibronectin (FN1), Collagen I (COL1), Collagen IV (COLIV) and PDGFRβ. Representative of N>2 different experiments. Scale bar 25 µm.
- D. Western blot showing expression of CAV1, CAVIN1, MGP, MMP2, SPARC, IGFBP7 and H3 for normalization. Cells from n=3 mice pooled per lane.
- E-F. Violin plot (E) and UMAP (F) of *Pdgfrb* expression on *in vitro* activated sc-RNAseq dataset.

1188

- 1189 G. Experimental scheme. MuSCs from adult *Tg:Pax7-nGFP* mice were activated *in vitro*, re-  
 1190 sorted based on their PDGFR $\beta$  expression and plated for further analysis.  
 1191 H. Representative images of PDGFR $\beta$  positive and negative EOM MuSC fractions stained for  
 1192 MYOD, MYOGENIN and EdU as per in G. Scale bar 50  $\mu$ m.  
 1193 I-L. Quantification of number of cells/cm<sup>2</sup> (I) and percentage of EdU<sup>+</sup> (J), MYOD<sup>+</sup> (K) and MYOG<sup>+</sup>  
 1194 (L) cells. n=3 mice.  
 1195 Data presented as mean  $\pm$  SEM. Two-tailed unpaired Student's t-test; ns, non-significant, p-  
 1196 value>0.05, \*\* p-value<0.01, \*\*\* p-value < 0.005.  
 1197

1198 **Figure 5. Distinct gene regulatory networks underlie EOM and TA activation dynamics.**

- 1199 A. Top 4 regulon activity for each cluster of the *in vitro* activated adult sc-RNaseq dataset  
 1200 overlaid onto UMAP representation.  
 1201 B. Heatmap of Top 7 regulons in each cluster with activity level in each cell. Myod1\_(+) appears  
 1202 twice as it is a regulon of both EOM Diff and TA Diff subpopulations.  
 1203 C. Transcription factor network highlighting top regulons of each cluster as well as common  
 1204 regulons (35 regulons maximum). Proximity of the nodes in the network indicates a higher  
 1205 number of shared edges, highlighting core modules.  
 1206

1207 **Figure 6. EOM properties are retained despite several passages *in vitro*.**

- 1208 A. Scheme of isolation and passages of EOM and TA adult MuSCs. Cells from *Tg:Pax7-*  
 1209 *nGFP;Myog<sup>ntdTom</sup>* were cultured for 3 days (Act) and the entire wells passaged (P1, P2) every  
 1210 3 days.  
 1211 B. Normalized cell number ratios from experiment in A. Total cell numbers per well were counted  
 1212 at day 3 (D3), days 5 (D5) and upon passages (P) and normalized on the averaged EOM cell  
 1213 number in all wells at each time point. n=3 mice.  
 1214 C. Ratio of tdTom<sup>+</sup>/GFP<sup>+</sup> cells per time point obtained through FACS analysis of *Tg:Pax7-*  
 1215 *nGFP;Myog<sup>ntdTom</sup>* EOM and TA adult MuSCs at D5, P1 and P2. n $\geq$ 3 mice.  
 1216 D. RT-qPCR at D3 (Act, Activated), P1 and P2 on whole cell populations for key myogenic  
 1217 markers, regulon TFs and matrisome genes identified in EOM progenitors isolated from adult  
 1218 *Tg:Pax7-nGFP* mice. n=4 mice.  
 1219 E-F. Western blot for TFs (E) and matrisome genes (F) on total P2 population from EOM and TA  
 1220 MuSCs isolated from adult *Tg:Pax7-nGFP* mice. ACTIN and TUBULIN were used for  
 1221 normalization of protein loading. n=3 mice.  
 1222 G. Densitometric analysis of the Western Blots in E-F.  
 1223 Data presented as mean  $\pm$  SEM. Two-tailed unpaired Student's t-test; ns, non-significant, p-  
 1224 value>0.05, \* p-value < 0.05, \*\* p-value<0.01, \*\*\* p-value < 0.005.  
 1225  
 1226

1227 **Figure 7. EOM activated features are present during postnatal growth and can be modulated by**  
 1228 **FOXC1.**

- 1229 A. Scheme of isolation of EOM and TA MuSCs from *Tg:Pax7-nGFP;Myog<sup>ntdTom</sup>* from postnatal  
 1230 day (P)7-P10 mice.  
 1231 B. RT-qPCR on GFP<sup>+</sup>/tdTom<sup>-</sup> cells. n>3 mice.  
 1232 C-D. Immunostaining for FOXC1, tdTom (TOM) and DYSTROPHIN on cryosections from EOM  
 1233 and TA muscles isolated from P10 (C) and adult (D) *Pax7<sup>CreERT2</sup>;R26<sup>tdTom</sup>* mice. White  
 1234 arrowheads point to PAX7+FOXC1+ cells. Black arrowheads point to PAX7+FOXC1-cells.  
 1235 Scale bars 50 $\mu$ m.  
 1236 E. Quantification of the experiment in D. n=4 mice.  
 1237 F. Scheme of lentivirus transduction for FOXC1 gain of function (GOF) experiments on adult TA  
 1238 MuSCs. The transduced cells (mCherry+) were re-isolated by FACS or directly analysed in  
 1239 mixed cultures.  
 1240 G-H. FACS plots of adult *Tg:Pax7-nGFP* TA MuSCs transduced with control (G) or GOF FOXC1  
 1241 (H) virus at D5. Both viruses carry an mCherry reporter.  
 1242 I. Western blot of transduced adult TA MuSCs for mCherry and Foxc1. VINCULIN was used for  
 1243 normalisation of protein loading. n $\geq$ 3 mice.  
 1244 J. RT-qPCR of transduced adult TA MuSCs for Myogenic Markers, Regulon Transcription factors  
 1245 (TFs) and key ECM proteins and regulators identified in EOM progenitors. n $\geq$ 3 mice.  
 1246 K-K'. Immunostaining of transduced adult TA MuSCs for FOXC1, EdU and Cell Mask Blue (CM-  
 1247 Blue, cytoplasmic stain). Scale bar 100 $\mu$ m.

1248 L. Immunostaining of transduced adult TA MuSCs grown in differentiation media for 48h and  
 1249 stained for MF20. Scale bar 100 $\mu$ m.  
 1250 M. Quantification of the Fusion Index for the images in L. n=4 mice.  
 1251 N-U. Quantification of cellular properties of adult TA MuSCs in mixed cultures containing  
 1252 transduced and non-transduced cells. (N, R) Violin plots showing the single cell distribution of  
 1253 FOXC1 fluorescence intensity. Bar plots of quantification of nucleus area (O, S), total number  
 1254 of nuclei (P, T) and percentage of EdU+ nuclei (Q, U). For N-Q n $\geq$ 4 mice, R-U n $\geq$ 3 mice.  
 1255 Dashed bar in P indicates total output in the mixed culture irrespective of FOXC1 expression.  
 1256 V-Y. Quantification of live imaging of adult TA MuSCs in mixed cultures containing transduced  
 1257 and non-transduced cells. Brightfield and red fluorescent channel images were acquired at 4  
 1258 different timepoints (+12, +24, +36, +48 hours) post transduction. (V-Y) Quantification of the  
 1259 relative abundance of mCherry+ and mCherry- cells (V) at 12h time point (t) and cell density  
 1260 (V,W) at all timepoints from movie images. n=3 mice.  
 1261 Z. Proposed model of the role of FOXC1 upon overexpression in TA MuSCs (TA GOF with re-  
 1262 sorting; TA GOF w/o re-sorting) and endogenously in EOM MuSCs.  
 1263 Data presented as mean  $\pm$  SEM. Two-tailed unpaired Student's t-test except in S,U where p values  
 1264 were obtained using one-way ANOVA with Tukey's post hoc; ns, non-significant, p-value>0.05, \* p-  
 1265 value < 0.05, \*\* p-value<0.01, \*\*\* p-value < 0.005, \*\*\*\* p-value<0.0001. GM, growth media; DM,  
 1266 differentiation media.  
 1267  
 1268  
 1269

1270 **Figure 8. RNA velocity reveals distinct population kinetics and potential key regulators of**  
 1271 **progenitor maintenance.**

1272 A. Number of regulatory links between regulons and matrisome genes depending on the number  
 1273 of top regulons in EOM and TA *in vitro* activated sc-RNAseq datasets.  
 1274 B. Ratio of number of regulations of matrisome genes between EOM and TA adult *in vitro*  
 1275 activated MuSCs. Maximal difference for top 5 first regulons.  
 1276 C. Heatmap of top regulons in global *in vitro* activated sc-RNAseq dataset with activity level in  
 1277 each cell.  
 1278 D-E. Velocity streams overlaid onto a UMAP representation for EOM (D) and TA (E), along with  
 1279 expression patterns of *Myog* and *Pax7* on *in vitro* activated adult sc-RNAseq dataset.  
 1280 F-G. Heatmap of driver gene expression from the velocity streams in D-E.  
 1281 H. Experimental scheme. MuSCs isolated from adult *Tg:Pax7-nGFP* mice were cultured for 3  
 1282 days to obtain EOM and TA conditioned media (CM). Hindlimb MuSCs were left untreated  
 1283 (control) or treated with CM from D1 to D4 post plating and pulsed with EdU 2h before fixation.  
 1284 I-J. Quantification of number of nuclei normalised on initial cell number (I) and percentage of  
 1285 EdU+ nuclei (J) of hindlimb MuSCs treated as per in H. N $\geq$ 2 independent experiments with  
 1286 n $\geq$ 2 mice each. Different symbol per experiment.  
 1287 K. Immunostaining of *Myf5<sup>nlacZ</sup>;Pdgfra<sup>H2BGFP</sup>* P3 mouse head cryosections for  $\beta$ -galactosidase ( $\beta$ -  
 1288 gal) and GFP. Scale bar 500 $\mu$ m. Higher magnifications in K'-K''. Scale bar 100 $\mu$ m.  
 1289 L. Quantification of the number of  $\beta$ -gal+ GFP+ cells per mm<sup>2</sup> in head muscles. n=3 mice.  
 1290 Data presented as mean  $\pm$  SEM. p values were obtained using one-way ANOVA with Tukey's post  
 1291 hoc; ns, non-significant, p-value>0.05, \*\* p-value<0.01, \*\*\* p-value < 0.005, \*\*\*\* p-value<0.0001.  
 1292  
 1293  
 1294




Figure 2





Figure 3








Figure 5

